https://trial.medpath.com/news/hippocampal-avoidance-during-brain-radiation-reduces-cognitive-toxicity-in-small-cell-lung-cancer-patients 2025-08-16T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hippocampal-avoidance-during-brain-radiation-reduces-cognitive-toxicity-in-small-cell-lung-cancer-patients 2025-08-16T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/trump-orders-strategic-stockpiling-of-essential-medicine-ingredients-to-reduce-foreign-dependence 2025-08-16T03:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-orders-strategic-stockpiling-of-essential-medicine-ingredients-to-reduce-foreign-dependence 2025-08-16T03:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/sonoma-pharmaceuticals-expands-hocl-technology-reach-with-major-us-retail-and-hospital-launches 2025-08-16T03:01:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonoma-pharmaceuticals-expands-hocl-technology-reach-with-major-us-retail-and-hospital-launches 2025-08-16T03:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/vcare-partners-with-huadong-medicine-for-vc005-jak1-inhibitor-commercialization-in-china 2025-08-16T01:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcare-partners-with-huadong-medicine-for-vc005-jak1-inhibitor-commercialization-in-china 2025-08-16T01:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-companies-face-surge-in-generic-drug-patent-challenges-in-early-2025 2025-08-16T01:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-companies-face-surge-in-generic-drug-patent-challenges-in-early-2025 2025-08-16T01:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/psma-pet-ct-before-salvage-radiotherapy-improves-survival-in-recurrent-prostate-cancer 2025-08-16T01:34:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psma-pet-ct-before-salvage-radiotherapy-improves-survival-in-recurrent-prostate-cancer 2025-08-16T01:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-bacteria-virus-system-cappsid-shows-promise-for-targeted-cancer-therapy 2025-08-16T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-bacteria-virus-system-cappsid-shows-promise-for-targeted-cancer-therapy 2025-08-16T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-exelixis-and-novartis-advance-pan-tumor-rollover-study-for-long-term-nivolumab-safety-assessment 2025-08-16T01:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-exelixis-and-novartis-advance-pan-tumor-rollover-study-for-long-term-nivolumab-safety-assessment 2025-08-16T01:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-s-wegovy-becomes-first-glp-1-therapy-approved-for-liver-disease-mash 2025-08-16T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-s-wegovy-becomes-first-glp-1-therapy-approved-for-liver-disease-mash 2025-08-16T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-advances-military-discussions-for-entolimod-as-radiation-countermeasure 2025-08-15T21:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-advances-military-discussions-for-entolimod-as-radiation-countermeasure 2025-08-15T21:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/australian-court-ruling-opens-entresto-to-generic-competition-invalidates-novartis-patent-extension 2025-08-15T21:45:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-court-ruling-opens-entresto-to-generic-competition-invalidates-novartis-patent-extension 2025-08-15T21:45:13+00:00 hourly 0.9 https://trial.medpath.com/news/federal-court-orders-fda-to-reconsider-vanda-s-hetlioz-application-for-jet-lag-disorder 2025-08-15T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-court-orders-fda-to-reconsider-vanda-s-hetlioz-application-for-jet-lag-disorder 2025-08-15T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/chop-researchers-discover-novel-rna-fragments-as-immunotherapy-targets-for-pediatric-brain-tumors 2025-08-15T21:43:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chop-researchers-discover-novel-rna-fragments-as-immunotherapy-targets-for-pediatric-brain-tumors 2025-08-15T21:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/sam-altman-s-merge-labs-explores-gene-therapy-approach-for-brain-computer-interface-technology 2025-08-15T21:41:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sam-altman-s-merge-labs-explores-gene-therapy-approach-for-brain-computer-interface-technology 2025-08-15T21:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/ascelia-pharma-nears-orviglance-nda-submission-for-orphan-liver-imaging-agent 2025-08-15T21:39:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascelia-pharma-nears-orviglance-nda-submission-for-orphan-liver-imaging-agent 2025-08-15T21:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-inclacumab-fails-phase-iii-trial-for-sickle-cell-disease-marking-second-setback-from-global-blood-therapeutics-acquisition 2025-08-15T21:38:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-inclacumab-fails-phase-iii-trial-for-sickle-cell-disease-marking-second-setback-from-global-blood-therapeutics-acquisition 2025-08-15T21:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/lumenis-dynamic-muscle-stimulation-technology-shows-promise-for-treating-dry-eye-disease-through-lower-lid-laxity-correction 2025-08-15T21:37:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lumenis-dynamic-muscle-stimulation-technology-shows-promise-for-treating-dry-eye-disease-through-lower-lid-laxity-correction 2025-08-15T21:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/nemvaleukin-alfa-shows-durable-antitumor-activity-in-advanced-melanoma-and-renal-cell-carcinoma 2025-08-15T18:27:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nemvaleukin-alfa-shows-durable-antitumor-activity-in-advanced-melanoma-and-renal-cell-carcinoma 2025-08-15T18:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-precigen-s-papzimeos-as-first-gene-therapy-for-recurrent-respiratory-papillomatosis 2025-08-15T18:15:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-precigen-s-papzimeos-as-first-gene-therapy-for-recurrent-respiratory-papillomatosis 2025-08-15T18:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/russian-supreme-court-upholds-compulsory-licensing-for-ozempic-generics-as-domestic-manufacturers-capture-semaglutide-market 2025-08-15T18:11:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russian-supreme-court-upholds-compulsory-licensing-for-ozempic-generics-as-domestic-manufacturers-capture-semaglutide-market 2025-08-15T18:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/rift-valley-fever-vaccine-enters-phase-ii-trials-in-kenya-using-oxford-s-chadox1-platform 2025-08-15T18:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rift-valley-fever-vaccine-enters-phase-ii-trials-in-kenya-using-oxford-s-chadox1-platform 2025-08-15T18:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pi3kd-inhibitor-roginolisib-shows-promise-in-phase-2-trial-for-metastatic-uveal-melanoma 2025-08-15T18:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pi3kd-inhibitor-roginolisib-shows-promise-in-phase-2-trial-for-metastatic-uveal-melanoma 2025-08-15T18:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-s-flumist-home-becomes-first-self-administered-flu-vaccine-available-for-home-delivery-in-us 2025-08-15T18:00:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-s-flumist-home-becomes-first-self-administered-flu-vaccine-available-for-home-delivery-in-us 2025-08-15T18:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/aha-acc-release-updated-2025-hypertension-guidelines-with-new-treatment-recommendations 2025-08-15T17:59:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aha-acc-release-updated-2025-hypertension-guidelines-with-new-treatment-recommendations 2025-08-15T17:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-comet-accelerates-rna-medicine-development-cutting-timelines-from-months-to-weeks 2025-08-15T13:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-comet-accelerates-rna-medicine-development-cutting-timelines-from-months-to-weeks 2025-08-15T13:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/sol-gel-completes-phase-3-enrollment-for-gorlin-syndrome-treatment-sgt-610-targets-300m-peak-revenue 2025-08-15T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sol-gel-completes-phase-3-enrollment-for-gorlin-syndrome-treatment-sgt-610-targets-300m-peak-revenue 2025-08-15T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/umass-chan-gene-therapy-shows-biochemical-correction-in-gm2-gangliosidosis-phase-i-ii-trial 2025-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/umass-chan-gene-therapy-shows-biochemical-correction-in-gm2-gangliosidosis-phase-i-ii-trial 2025-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-show-promise-as-novel-treatment-for-hidradenitis-suppurativa 2025-08-15T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-promise-as-novel-treatment-for-hidradenitis-suppurativa 2025-08-15T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/istios-health-expands-infectious-disease-research-network-through-strategic-partnerships-in-georgia-and-virginia 2025-08-15T09:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/istios-health-expands-infectious-disease-research-network-through-strategic-partnerships-in-georgia-and-virginia 2025-08-15T09:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-alk-targeted-antibody-drug-conjugate-demonstrates-complete-tumor-regression-in-preclinical-cancer-models 2025-08-15T09:36:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-alk-targeted-antibody-drug-conjugate-demonstrates-complete-tumor-regression-in-preclinical-cancer-models 2025-08-15T09:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/innogen-pharmaceutical-soars-296-in-hong-kong-debut-following-glp-1-diabetes-drug-approval 2025-08-15T09:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innogen-pharmaceutical-soars-296-in-hong-kong-debut-following-glp-1-diabetes-drug-approval 2025-08-15T09:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/restem-receives-fda-orphan-drug-designation-for-stem-cell-therapy-in-polymyositis-treatment 2025-08-15T08:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-receives-fda-orphan-drug-designation-for-stem-cell-therapy-in-polymyositis-treatment 2025-08-15T08:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-designed-antibiotics-show-promise-against-drug-resistant-gonorrhea-and-mrsa-in-laboratory-studies 2025-08-15T05:37:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-designed-antibiotics-show-promise-against-drug-resistant-gonorrhea-and-mrsa-in-laboratory-studies 2025-08-15T05:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-requires-confirmatory-study-for-minerva-s-roluperidone-in-schizophrenia-as-company-explores-strategic-alternatives 2025-08-15T05:36:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-requires-confirmatory-study-for-minerva-s-roluperidone-in-schizophrenia-as-company-explores-strategic-alternatives 2025-08-15T05:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/delaware-court-rules-pfizer-covid-19-vaccine-does-not-infringe-alnylam-s-nanoparticle-patents 2025-08-15T05:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delaware-court-rules-pfizer-covid-19-vaccine-does-not-infringe-alnylam-s-nanoparticle-patents 2025-08-15T05:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/archer-trial-opens-enrollment-to-test-shortened-radiation-therapy-for-muscle-invasive-bladder-cancer 2025-08-15T05:35:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/archer-trial-opens-enrollment-to-test-shortened-radiation-therapy-for-muscle-invasive-bladder-cancer 2025-08-15T05:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/citizen-health-raises-30m-series-a-to-develop-ai-advocate-for-rare-disease-patients 2025-08-15T05:35:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citizen-health-raises-30m-series-a-to-develop-ai-advocate-for-rare-disease-patients 2025-08-15T05:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/mink-therapeutics-reports-clinical-progress-with-inkt-cell-therapy-targets-phase-ii-gastric-cancer-data-by-end-of-2025 2025-08-15T05:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mink-therapeutics-reports-clinical-progress-with-inkt-cell-therapy-targets-phase-ii-gastric-cancer-data-by-end-of-2025 2025-08-15T05:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/patient-perspectives-reveal-gaps-in-ckd-education-despite-support-for-collaborative-care 2025-08-15T03:02:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-perspectives-reveal-gaps-in-ckd-education-despite-support-for-collaborative-care 2025-08-15T03:02:18+00:00 hourly 0.9 https://trial.medpath.com/news/international-expert-panel-issues-new-guidelines-for-sglt-2-and-glp-1-use-in-type-2-diabetes-based-on-cardiovascular-risk 2025-08-15T03:01:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/international-expert-panel-issues-new-guidelines-for-sglt-2-and-glp-1-use-in-type-2-diabetes-based-on-cardiovascular-risk 2025-08-15T03:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/rubicon-research-secures-250-crore-pre-ipo-investment-from-amansa-reduces-fresh-issue-size-ahead-of-year-end-public-listing 2025-08-15T01:38:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rubicon-research-secures-250-crore-pre-ipo-investment-from-amansa-reduces-fresh-issue-size-ahead-of-year-end-public-listing 2025-08-15T01:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/repare-therapeutics-reports-52-reduction-in-q2-loss-amid-strategic-pivot-to-licensing-model 2025-08-15T01:38:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/repare-therapeutics-reports-52-reduction-in-q2-loss-amid-strategic-pivot-to-licensing-model 2025-08-15T01:38:04+00:00 hourly 0.9 https://trial.medpath.com/news/cue-biopharma-initiates-phase-1b-trial-of-cue-102-for-recurrent-glioblastoma-at-dana-farber 2025-08-15T01:37:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cue-biopharma-initiates-phase-1b-trial-of-cue-102-for-recurrent-glioblastoma-at-dana-farber 2025-08-15T01:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/paldara-and-mayo-clinic-advance-bacteriophage-hydrogel-platform-toward-first-human-trials 2025-08-15T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paldara-and-mayo-clinic-advance-bacteriophage-hydrogel-platform-toward-first-human-trials 2025-08-15T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/spruce-biosciences-reports-breakthrough-long-term-data-for-ta-ert-in-rare-sanfilippo-syndrome-type-b 2025-08-15T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spruce-biosciences-reports-breakthrough-long-term-data-for-ta-ert-in-rare-sanfilippo-syndrome-type-b 2025-08-15T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/smart-t-smoking-cessation-app-shows-nearly-double-quit-rates-in-low-income-adults 2025-08-15T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-t-smoking-cessation-app-shows-nearly-double-quit-rates-in-low-income-adults 2025-08-15T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis 2025-08-15T01:30:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis 2025-08-15T01:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-m-a-surge-and-landmark-antitrust-rulings-shape-2025-life-sciences-landscape 2025-08-14T21:41:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-m-a-surge-and-landmark-antitrust-rulings-shape-2025-life-sciences-landscape 2025-08-14T21:41:41+00:00 hourly 0.9 https://trial.medpath.com/news/saniona-secures-1-billion-licensing-deal-with-jazz-pharmaceuticals-in-major-biotech-partnership 2025-08-14T21:39:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saniona-secures-1-billion-licensing-deal-with-jazz-pharmaceuticals-in-major-biotech-partnership 2025-08-14T21:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/acelink-therapeutics-al01211-shows-promising-safety-and-biomarker-reduction-in-phase-2-fabry-disease-trial 2025-08-14T21:39:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acelink-therapeutics-al01211-shows-promising-safety-and-biomarker-reduction-in-phase-2-fabry-disease-trial 2025-08-14T21:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/novel-oral-polio-vaccines-demonstrate-safety-and-efficacy-in-first-in-human-phase-1-trial 2025-08-14T21:39:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-oral-polio-vaccines-demonstrate-safety-and-efficacy-in-first-in-human-phase-1-trial 2025-08-14T21:39:04+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-based-casgevy-emerges-as-preferred-gene-therapy-for-beta-thalassemia-survey-shows 2025-08-14T21:37:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-based-casgevy-emerges-as-preferred-gene-therapy-for-beta-thalassemia-survey-shows 2025-08-14T21:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/swri-develops-games-ai-model-to-accelerate-drug-discovery-through-smiles-generation 2025-08-14T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/swri-develops-games-ai-model-to-accelerate-drug-discovery-through-smiles-generation 2025-08-14T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/kiffik-biomedical-strengthens-leadership-with-strategic-appointments-to-advance-interstitial-fluid-diagnostics 2025-08-14T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiffik-biomedical-strengthens-leadership-with-strategic-appointments-to-advance-interstitial-fluid-diagnostics 2025-08-14T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/macrogenics-names-eric-risser-as-new-ceo-succeeding-24-year-leader-scott-koenig 2025-08-14T17:10:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/macrogenics-names-eric-risser-as-new-ceo-succeeding-24-year-leader-scott-koenig 2025-08-14T17:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-secures-upc-court-victory-protecting-nintedanib-patent-against-generic-competition 2025-08-14T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-secures-upc-court-victory-protecting-nintedanib-patent-against-generic-competition 2025-08-14T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/scpharmaceuticals-secures-five-new-patents-for-heart-failure-drug-scp-111 2025-08-14T17:10:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scpharmaceuticals-secures-five-new-patents-for-heart-failure-drug-scp-111 2025-08-14T17:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/peak-car-t-cell-expansion-linked-to-improved-outcomes-in-b-all-patients-receiving-brexu-cel 2025-08-14T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/peak-car-t-cell-expansion-linked-to-improved-outcomes-in-b-all-patients-receiving-brexu-cel 2025-08-14T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/schrodinger-discontinues-blood-cancer-drug-sgr-2921-after-two-patient-deaths-in-phase-i-trial 2025-08-14T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schrodinger-discontinues-blood-cancer-drug-sgr-2921-after-two-patient-deaths-in-phase-i-trial 2025-08-14T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/lantern-pharma-reports-complete-responses-in-two-cancer-trials-advances-ai-driven-pipeline 2025-08-14T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantern-pharma-reports-complete-responses-in-two-cancer-trials-advances-ai-driven-pipeline 2025-08-14T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/engineered-cd40-antibody-achieves-complete-cancer-remission-in-phase-1-trial 2025-08-14T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/engineered-cd40-antibody-achieves-complete-cancer-remission-in-phase-1-trial 2025-08-14T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/pds-biotechnology-s-versamune-hpv-shows-30-month-median-survival-in-phase-2-head-and-neck-cancer-trial 2025-08-14T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pds-biotechnology-s-versamune-hpv-shows-30-month-median-survival-in-phase-2-head-and-neck-cancer-trial 2025-08-14T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/on-demand-pharmaceuticals-demonstrates-point-of-care-manufacturing-platform-to-hhs-officials 2025-08-14T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/on-demand-pharmaceuticals-demonstrates-point-of-care-manufacturing-platform-to-hhs-officials 2025-08-14T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-biosimilar-ly01011-demonstrates-therapeutic-equivalence-in-phase-3-bone-metastases-trial 2025-08-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-biosimilar-ly01011-demonstrates-therapeutic-equivalence-in-phase-3-bone-metastases-trial 2025-08-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-pharmaceutica-acquires-global-rights-to-phase-3-ready-oral-antibiotic-for-drug-resistant-utis 2025-08-14T17:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-pharmaceutica-acquires-global-rights-to-phase-3-ready-oral-antibiotic-for-drug-resistant-utis 2025-08-14T17:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/herantis-pharma-completes-phase-1b-trial-of-her-096-for-parkinson-s-disease-topline-results-expected-within-nine-weeks 2025-08-14T17:02:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/herantis-pharma-completes-phase-1b-trial-of-her-096-for-parkinson-s-disease-topline-results-expected-within-nine-weeks 2025-08-14T17:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/ignitedata-secures-series-a-funding-to-expand-clinical-trial-data-automation-platform-globally 2025-08-14T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ignitedata-secures-series-a-funding-to-expand-clinical-trial-data-automation-platform-globally 2025-08-14T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/vedanta-biosciences-cuts-20-of-workforce-after-microbiome-therapy-ve202-fails-phase-2-ulcerative-colitis-trial 2025-08-14T17:01:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedanta-biosciences-cuts-20-of-workforce-after-microbiome-therapy-ve202-fails-phase-2-ulcerative-colitis-trial 2025-08-14T17:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-t1d-publishes-clinical-trial-roadmap-for-next-generation-beta-cell-replacement-therapies 2025-08-14T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-t1d-publishes-clinical-trial-roadmap-for-next-generation-beta-cell-replacement-therapies 2025-08-14T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/dual-checkpoint-inhibitor-therapy-fails-to-improve-outcomes-in-mgmt-unmethylated-glioblastoma 2025-08-14T13:39:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-checkpoint-inhibitor-therapy-fails-to-improve-outcomes-in-mgmt-unmethylated-glioblastoma 2025-08-14T13:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/aquestive-therapeutics-secures-75m-strategic-funding-from-rtw-for-anaphylm-commercial-launch 2025-08-14T13:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aquestive-therapeutics-secures-75m-strategic-funding-from-rtw-for-anaphylm-commercial-launch 2025-08-14T13:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/evolveimmune-receives-fda-clearance-for-novel-trispecific-t-cell-engager-evolve104-targeting-solid-tumors 2025-08-14T13:33:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolveimmune-receives-fda-clearance-for-novel-trispecific-t-cell-engager-evolve104-targeting-solid-tumors 2025-08-14T13:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/goa-becomes-india-s-first-state-to-implement-pricing-policy-for-high-cost-cancer-and-rare-disease-therapies 2025-08-14T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/goa-becomes-india-s-first-state-to-implement-pricing-policy-for-high-cost-cancer-and-rare-disease-therapies 2025-08-14T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-s-15-day-cgm-eliminates-fingerstick-calibration-in-clinical-trial 2025-08-14T09:06:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-s-15-day-cgm-eliminates-fingerstick-calibration-in-clinical-trial 2025-08-14T09:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-accepts-everest-medicines-velsipity-application-for-ulcerative-colitis-treatment 2025-08-14T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-accepts-everest-medicines-velsipity-application-for-ulcerative-colitis-treatment 2025-08-14T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/reprieve-cardiovascular-secures-61-million-series-b-funding-initiates-pivotal-heart-failure-trial 2025-08-14T09:04:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reprieve-cardiovascular-secures-61-million-series-b-funding-initiates-pivotal-heart-failure-trial 2025-08-14T09:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/daewoong-s-microneedle-patch-achieves-80-bioavailability-for-semaglutide-setting-new-standard-for-needle-free-obesity-treatment 2025-08-14T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daewoong-s-microneedle-patch-achieves-80-bioavailability-for-semaglutide-setting-new-standard-for-needle-free-obesity-treatment 2025-08-14T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-s-yutrepia-achieves-rapid-market-uptake-with-900-prescriptions-in-11-weeks-post-approval 2025-08-14T05:05:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-s-yutrepia-achieves-rapid-market-uptake-with-900-prescriptions-in-11-weeks-post-approval 2025-08-14T05:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-settles-patent-dispute-with-laurus-labs-over-hiv-drug-tenofovir 2025-08-14T05:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-settles-patent-dispute-with-laurus-labs-over-hiv-drug-tenofovir 2025-08-14T05:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/ebus-guided-lung-biopsies-demonstrate-superior-safety-profile-for-comprehensive-biomarker-testing 2025-08-14T03:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebus-guided-lung-biopsies-demonstrate-superior-safety-profile-for-comprehensive-biomarker-testing 2025-08-14T03:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/oncology-experts-address-operational-challenges-in-value-based-cancer-care-implementation 2025-08-14T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncology-experts-address-operational-challenges-in-value-based-cancer-care-implementation 2025-08-14T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-initiates-phase-2-trial-of-alg-000184-for-chronic-hepatitis-b-treatment 2025-08-14T01:18:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-initiates-phase-2-trial-of-alg-000184-for-chronic-hepatitis-b-treatment 2025-08-14T01:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-therapeutics-reports-positive-phase-3-xyngari-trial-results-for-moderate-to-severe-acne-treatment 2025-08-14T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermata-therapeutics-reports-positive-phase-3-xyngari-trial-results-for-moderate-to-severe-acne-treatment 2025-08-14T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/alvotech-reports-record-first-half-2025-results-with-over-200-product-revenue-growth 2025-08-14T01:11:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alvotech-reports-record-first-half-2025-results-with-over-200-product-revenue-growth 2025-08-14T01:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/allogene-therapeutics-reports-narrowed-q2-loss-despite-clinical-trial-delays-for-car-t-programs 2025-08-14T01:10:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allogene-therapeutics-reports-narrowed-q2-loss-despite-clinical-trial-delays-for-car-t-programs 2025-08-14T01:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/anlotinib-plus-epirubicin-receives-world-s-first-approval-in-china-for-advanced-soft-tissue-sarcoma 2025-08-14T01:10:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anlotinib-plus-epirubicin-receives-world-s-first-approval-in-china-for-advanced-soft-tissue-sarcoma 2025-08-14T01:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/mediwound-s-escharex-phase-ii-data-reveals-strong-correlation-between-wound-bed-preparation-and-healing-in-venous-leg-ulcers 2025-08-14T01:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediwound-s-escharex-phase-ii-data-reveals-strong-correlation-between-wound-bed-preparation-and-healing-in-venous-leg-ulcers 2025-08-14T01:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/baptist-health-hardin-launches-world-s-first-4d-mammography-clinical-trial-using-x-ray-diffraction-technology 2025-08-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baptist-health-hardin-launches-world-s-first-4d-mammography-clinical-trial-using-x-ray-diffraction-technology 2025-08-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vyome-therapeutics-secures-nasdaq-approval-for-merger-with-reshape-lifesciences-targeting-100b-inflammatory-disease-market 2025-08-13T21:45:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyome-therapeutics-secures-nasdaq-approval-for-merger-with-reshape-lifesciences-targeting-100b-inflammatory-disease-market 2025-08-13T21:45:03+00:00 hourly 0.9 https://trial.medpath.com/news/helix-biopharma-s-l-dos47-shows-promising-survival-extension-in-advanced-nsclc-phase-i-ii-study 2025-08-13T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/helix-biopharma-s-l-dos47-shows-promising-survival-extension-in-advanced-nsclc-phase-i-ii-study 2025-08-13T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/vedanta-biosciences-ve202-fails-phase-2-trial-for-ulcerative-colitis-company-refocuses-on-c-difficile-program 2025-08-13T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedanta-biosciences-ve202-fails-phase-2-trial-for-ulcerative-colitis-company-refocuses-on-c-difficile-program 2025-08-13T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/biocardia-and-cart-tech-form-exclusive-partnership-for-heart3d-fusion-imaging-technology-in-cardiac-biotherapeutic-delivery 2025-08-13T21:39:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocardia-and-cart-tech-form-exclusive-partnership-for-heart3d-fusion-imaging-technology-in-cardiac-biotherapeutic-delivery 2025-08-13T21:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/australian-biotech-mirugen-raises-a-4-5m-to-advance-cell-reprogramming-therapy-for-retinal-diseases 2025-08-13T21:38:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-biotech-mirugen-raises-a-4-5m-to-advance-cell-reprogramming-therapy-for-retinal-diseases 2025-08-13T21:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharmaceutical-patent-settlements-reshape-generic-drug-market-in-q2-q3-2025 2025-08-13T21:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharmaceutical-patent-settlements-reshape-generic-drug-market-in-q2-q3-2025 2025-08-13T21:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letters-to-sunscreen-companies-over-unapproved-mousse-formulations 2025-08-13T21:34:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letters-to-sunscreen-companies-over-unapproved-mousse-formulations 2025-08-13T21:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/cit-therapeutics-secures-2-5m-partnership-with-ifli-to-advance-novel-sumoylation-targeted-cancer-therapy 2025-08-13T21:34:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cit-therapeutics-secures-2-5m-partnership-with-ifli-to-advance-novel-sumoylation-targeted-cancer-therapy 2025-08-13T21:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/duke-nus-receives-1-5m-to-advance-ai-powered-antifibrotic-drug-discovery-platform 2025-08-13T17:42:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/duke-nus-receives-1-5m-to-advance-ai-powered-antifibrotic-drug-discovery-platform 2025-08-13T17:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/dallas-cowboys-owner-jerry-jones-credits-pd-1-immunotherapy-for-stage-4-melanoma-survival 2025-08-13T17:42:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dallas-cowboys-owner-jerry-jones-credits-pd-1-immunotherapy-for-stage-4-melanoma-survival 2025-08-13T17:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-urgent-correction-for-tandem-t-slim-x2-insulin-pump-following-700-adverse-events 2025-08-13T17:41:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-urgent-correction-for-tandem-t-slim-x2-insulin-pump-following-700-adverse-events 2025-08-13T17:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/curacell-receives-german-approval-for-phase-i-iia-trial-of-cc-38-til-therapy-in-metastatic-cancers 2025-08-13T17:40:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/curacell-receives-german-approval-for-phase-i-iia-trial-of-cc-38-til-therapy-in-metastatic-cancers 2025-08-13T17:40:18+00:00 hourly 0.9 https://trial.medpath.com/news/st-jude-develops-ai-powered-tool-to-accelerate-dual-target-car-t-cell-therapy-design 2025-08-13T17:39:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/st-jude-develops-ai-powered-tool-to-accelerate-dual-target-car-t-cell-therapy-design 2025-08-13T17:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/neuronascent-s-nni-362-shows-promise-in-phase-1a-trial-for-alzheimer-s-disease-with-novel-neuron-regeneration-approach 2025-08-13T17:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuronascent-s-nni-362-shows-promise-in-phase-1a-trial-for-alzheimer-s-disease-with-novel-neuron-regeneration-approach 2025-08-13T17:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/apertura-gene-therapy-licenses-blood-brain-barrier-penetrant-aav-capsid-to-multiple-partners-for-cns-treatments 2025-08-13T17:38:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apertura-gene-therapy-licenses-blood-brain-barrier-penetrant-aav-capsid-to-multiple-partners-for-cns-treatments 2025-08-13T17:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/nine-year-old-becomes-third-patient-worldwide-to-receive-experimental-gene-therapy-for-rare-batten-disease 2025-08-13T17:38:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nine-year-old-becomes-third-patient-worldwide-to-receive-experimental-gene-therapy-for-rare-batten-disease 2025-08-13T17:38:01+00:00 hourly 0.9 https://trial.medpath.com/news/elevatebio-basecamp-becomes-first-genetic-medicine-manufacturer-to-achieve-comprehensive-icmc-certification-across-multiple-modalities 2025-08-13T17:37:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevatebio-basecamp-becomes-first-genetic-medicine-manufacturer-to-achieve-comprehensive-icmc-certification-across-multiple-modalities 2025-08-13T17:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/avista-therapeutics-partners-with-forge-biologics-to-advance-avst-101-gene-therapy-for-x-linked-retinoschisis 2025-08-13T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avista-therapeutics-partners-with-forge-biologics-to-advance-avst-101-gene-therapy-for-x-linked-retinoschisis 2025-08-13T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/x4-pharmaceuticals-secures-85-million-private-placement-to-advance-mavorixafor-development 2025-08-13T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x4-pharmaceuticals-secures-85-million-private-placement-to-advance-mavorixafor-development 2025-08-13T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/news/pilatus-biosciences-partners-with-roche-for-first-in-human-trial-of-plt012-in-hepatocellular-carcinoma 2025-08-13T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pilatus-biosciences-partners-with-roche-for-first-in-human-trial-of-plt012-in-hepatocellular-carcinoma 2025-08-13T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/caris-life-sciences-study-reveals-optimal-sequencing-strategy-for-antibody-drug-conjugates-in-her2-negative-breast-cancer 2025-08-13T17:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caris-life-sciences-study-reveals-optimal-sequencing-strategy-for-antibody-drug-conjugates-in-her2-negative-breast-cancer 2025-08-13T17:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-biodynamics-partners-with-google-cloud-to-scale-ai-powered-3d-genomic-analytics-platform 2025-08-13T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-biodynamics-partners-with-google-cloud-to-scale-ai-powered-3d-genomic-analytics-platform 2025-08-13T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-technology-secures-fda-fast-track-designation-for-celz-201-ddt-back-pain-therapy 2025-08-13T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-medical-technology-secures-fda-fast-track-designation-for-celz-201-ddt-back-pain-therapy 2025-08-13T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/pulse-biosciences-advances-nspfa-technology-with-fda-breakthrough-designation-and-clinical-expansion 2025-08-13T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulse-biosciences-advances-nspfa-technology-with-fda-breakthrough-designation-and-clinical-expansion 2025-08-13T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/uc-cancer-center-launches-phase-3-trial-testing-high-dose-radiation-for-locally-advanced-pancreatic-cancer 2025-08-13T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-cancer-center-launches-phase-3-trial-testing-high-dose-radiation-for-locally-advanced-pancreatic-cancer 2025-08-13T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/ars-pharmaceuticals-reports-strong-q3-2025-growth-for-needle-free-epinephrine-nasal-spray-neffy 2025-08-13T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ars-pharmaceuticals-reports-strong-q3-2025-growth-for-needle-free-epinephrine-nasal-spray-neffy 2025-08-13T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-s-cd19-car-nk-therapy-achieves-complete-responses-in-late-stage-waldenstrom-macroglobulinemia 2025-08-13T17:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-s-cd19-car-nk-therapy-achieves-complete-responses-in-late-stage-waldenstrom-macroglobulinemia 2025-08-13T17:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/two-dose-dalbavancin-matches-standard-therapy-for-complicated-staphylococcus-aureus-bloodstream-infections 2025-08-13T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-dose-dalbavancin-matches-standard-therapy-for-complicated-staphylococcus-aureus-bloodstream-infections 2025-08-13T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/high-volume-cancer-centers-with-greater-neoadjuvant-chemotherapy-use-show-reduced-mortality-in-advanced-ovarian-cancer 2025-08-13T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-volume-cancer-centers-with-greater-neoadjuvant-chemotherapy-use-show-reduced-mortality-in-advanced-ovarian-cancer 2025-08-13T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-government-and-eli-lilly-launch-ps85-million-partnership-to-transform-obesity-care-access 2025-08-13T13:37:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-government-and-eli-lilly-launch-ps85-million-partnership-to-transform-obesity-care-access 2025-08-13T13:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/iptacopan-shows-promise-in-treating-life-threatening-transplant-associated-thrombotic-microangiopathy 2025-08-13T13:35:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iptacopan-shows-promise-in-treating-life-threatening-transplant-associated-thrombotic-microangiopathy 2025-08-13T13:35:50+00:00 hourly 0.9 https://trial.medpath.com/news/hku-researchers-discover-atorvastatin-s-potential-as-novel-liver-cancer-treatment 2025-08-13T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hku-researchers-discover-atorvastatin-s-potential-as-novel-liver-cancer-treatment 2025-08-13T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/canbridge-pharmaceuticals-secures-12-7m-strategic-investment-from-baheal-medical-to-accelerate-rare-disease-drug-commercialization 2025-08-13T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canbridge-pharmaceuticals-secures-12-7m-strategic-investment-from-baheal-medical-to-accelerate-rare-disease-drug-commercialization 2025-08-13T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/china-approves-first-miniature-spinal-surgical-robot-with-sub-millimeter-precision 2025-08-13T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-approves-first-miniature-spinal-surgical-robot-with-sub-millimeter-precision 2025-08-13T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/variable-long-covid-definitions-hamper-clinical-care-and-research-progress 2025-08-13T13:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/variable-long-covid-definitions-hamper-clinical-care-and-research-progress 2025-08-13T13:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-infiltrating-lymphocyte-therapy-market-poised-for-explosive-growth-following-first-fda-approval 2025-08-13T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-infiltrating-lymphocyte-therapy-market-poised-for-explosive-growth-following-first-fda-approval 2025-08-13T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/btl-industries-receives-fda-clearance-to-expand-emface-platform-for-tmj-dysfunction-treatment 2025-08-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/btl-industries-receives-fda-clearance-to-expand-emface-platform-for-tmj-dysfunction-treatment 2025-08-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/polypid-appoints-dr-nurit-tweezer-zaks-as-chief-medical-officer-following-positive-phase-3-results 2025-08-13T05:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polypid-appoints-dr-nurit-tweezer-zaks-as-chief-medical-officer-following-positive-phase-3-results 2025-08-13T05:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/avendus-fund-and-sbi-life-invest-300-crore-in-indian-crdmo-aragen-life-sciences 2025-08-13T05:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avendus-fund-and-sbi-life-invest-300-crore-in-indian-crdmo-aragen-life-sciences 2025-08-13T05:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/ulcerative-colitis-treatment-market-reaches-8-4-billion-as-pipeline-expands-with-75-novel-therapies 2025-08-13T05:30:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ulcerative-colitis-treatment-market-reaches-8-4-billion-as-pipeline-expands-with-75-novel-therapies 2025-08-13T05:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/zevra-therapeutics-reports-strong-q2-2025-results-seeks-european-approval-for-miplyffa 2025-08-13T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zevra-therapeutics-reports-strong-q2-2025-results-seeks-european-approval-for-miplyffa 2025-08-13T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/snmmi-launches-ai-powered-platform-to-connect-patients-with-radiopharmaceutical-clinical-trials 2025-08-13T05:29:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snmmi-launches-ai-powered-platform-to-connect-patients-with-radiopharmaceutical-clinical-trials 2025-08-13T05:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/imf-s-m-power-initiative-tackles-multiple-myeloma-disparities-in-black-communities-through-trust-building-and-clinical-trial-access 2025-08-13T03:02:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imf-s-m-power-initiative-tackles-multiple-myeloma-disparities-in-black-communities-through-trust-building-and-clinical-trial-access 2025-08-13T03:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-ovarian-cancer-treatment 2025-08-13T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-ovarian-cancer-treatment 2025-08-13T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/coya-therapeutics-awaits-fda-decision-on-als-treatment-as-q2-results-show-mixed-performance 2025-08-13T01:35:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coya-therapeutics-awaits-fda-decision-on-als-treatment-as-q2-results-show-mixed-performance 2025-08-13T01:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/southern-research-opens-98-million-biotechnology-center-in-birmingham-to-accelerate-drug-discovery 2025-08-13T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/southern-research-opens-98-million-biotechnology-center-in-birmingham-to-accelerate-drug-discovery 2025-08-13T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-safety-and-efficacy-of-biologic-switching-in-psoriasis-treatment 2025-08-13T01:30:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-safety-and-efficacy-of-biologic-switching-in-psoriasis-treatment 2025-08-13T01:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/who-endorses-first-new-malaria-vector-control-tool-in-four-decades-as-spatial-repellents-show-56-protection-rate 2025-08-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-endorses-first-new-malaria-vector-control-tool-in-four-decades-as-spatial-repellents-show-56-protection-rate 2025-08-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uc-davis-researchers-discover-gut-bacteria-molecule-that-reverses-liver-damage-and-repairs-intestinal-barrier 2025-08-12T21:38:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-davis-researchers-discover-gut-bacteria-molecule-that-reverses-liver-damage-and-repairs-intestinal-barrier 2025-08-12T21:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/met-inhibitor-shows-promise-in-enhancing-small-cell-lung-cancer-treatment-response 2025-08-12T21:36:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/met-inhibitor-shows-promise-in-enhancing-small-cell-lung-cancer-treatment-response 2025-08-12T21:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/atossa-therapeutics-streamlines-phase-ii-breast-cancer-trial-design-while-advancing-z-endoxifen-development 2025-08-12T21:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atossa-therapeutics-streamlines-phase-ii-breast-cancer-trial-design-while-advancing-z-endoxifen-development 2025-08-12T21:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-invests-195-million-to-expand-u-s-api-manufacturing-capacity-in-north-chicago 2025-08-12T21:35:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-invests-195-million-to-expand-u-s-api-manufacturing-capacity-in-north-chicago 2025-08-12T21:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-initiates-first-us-clinical-trial-of-nectin-4-adc-in-previously-treated-triple-negative-breast-cancer 2025-08-12T21:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-initiates-first-us-clinical-trial-of-nectin-4-adc-in-previously-treated-triple-negative-breast-cancer 2025-08-12T21:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/bostongene-validates-multimodal-rna-dna-tumor-assay-in-landmark-study-across-2200-cancer-samples 2025-08-12T21:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bostongene-validates-multimodal-rna-dna-tumor-assay-in-landmark-study-across-2200-cancer-samples 2025-08-12T21:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/sareum-partners-with-receptor-ai-to-accelerate-ai-driven-discovery-of-brain-penetrating-tyk2-jak1-inhibitors-for-neuroinflammatory-diseases 2025-08-12T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sareum-partners-with-receptor-ai-to-accelerate-ai-driven-discovery-of-brain-penetrating-tyk2-jak1-inhibitors-for-neuroinflammatory-diseases 2025-08-12T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-emerges-as-major-drug-licensing-hub-with-7-68-billion-in-deals-driven-by-eli-lilly-and-gsk 2025-08-12T21:33:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-emerges-as-major-drug-licensing-hub-with-7-68-billion-in-deals-driven-by-eli-lilly-and-gsk 2025-08-12T21:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/ph-d-feminine-health-initiates-first-fda-cleared-phase-3-trial-for-boric-acid-suppositories-in-yeast-infections 2025-08-12T21:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ph-d-feminine-health-initiates-first-fda-cleared-phase-3-trial-for-boric-acid-suppositories-in-yeast-infections 2025-08-12T21:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/acumen-pharmaceuticals-advances-alzheimer-s-pipeline-with-jcr-partnership-and-altitude-ad-phase-2-trial 2025-08-12T21:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acumen-pharmaceuticals-advances-alzheimer-s-pipeline-with-jcr-partnership-and-altitude-ad-phase-2-trial 2025-08-12T21:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/lung-fibrosis-drug-pirfenidone-shows-promise-as-copd-treatment-alternative-to-steroids 2025-08-12T21:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-fibrosis-drug-pirfenidone-shows-promise-as-copd-treatment-alternative-to-steroids 2025-08-12T21:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/early-long-covid-trials-of-paxlovid-and-monoclonal-antibodies-show-no-significant-benefits-but-research-continues 2025-08-12T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-long-covid-trials-of-paxlovid-and-monoclonal-antibodies-show-no-significant-benefits-but-research-continues 2025-08-12T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/mail-order-and-digital-pharmacies-surge-ahead-as-chain-drugstores-face-customer-satisfaction-crisis 2025-08-12T20:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mail-order-and-digital-pharmacies-surge-ahead-as-chain-drugstores-face-customer-satisfaction-crisis 2025-08-12T20:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/hope-trial-extends-alteplase-treatment-window-to-24-hours-for-acute-ischemic-stroke-patients 2025-08-12T17:43:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-trial-extends-alteplase-treatment-window-to-24-hours-for-acute-ischemic-stroke-patients 2025-08-12T17:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/gameto-secures-44m-series-c-funding-as-stem-cell-ivf-therapy-fertilo-advances-to-phase-3-trial 2025-08-12T17:43:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gameto-secures-44m-series-c-funding-as-stem-cell-ivf-therapy-fertilo-advances-to-phase-3-trial 2025-08-12T17:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/v116-pneumococcal-vaccine-demonstrates-superior-immunogenicity-in-japanese-adults-65-and-older 2025-08-12T17:42:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/v116-pneumococcal-vaccine-demonstrates-superior-immunogenicity-in-japanese-adults-65-and-older 2025-08-12T17:42:45+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-halts-vaxart-s-460-million-oral-covid-19-vaccine-trial-amid-federal-mrna-program-rollback 2025-08-12T17:42:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-halts-vaxart-s-460-million-oral-covid-19-vaccine-trial-amid-federal-mrna-program-rollback 2025-08-12T17:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapies-enhance-oncolytic-virus-cancer-treatment-through-immune-system-reprogramming 2025-08-12T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapies-enhance-oncolytic-virus-cancer-treatment-through-immune-system-reprogramming 2025-08-12T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/x4-pharmaceuticals-secures-60-million-financing-and-installs-new-leadership-team 2025-08-12T17:39:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/x4-pharmaceuticals-secures-60-million-financing-and-installs-new-leadership-team 2025-08-12T17:39:19+00:00 hourly 0.9 https://trial.medpath.com/news/imdx-enrolls-first-patient-in-graftassuredx-transplant-rejection-monitoring-trial 2025-08-12T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdx-enrolls-first-patient-in-graftassuredx-transplant-rejection-monitoring-trial 2025-08-12T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-secures-645m-deal-for-chinese-dpp-1-inhibitor-in-growing-cross-border-biotech-trend 2025-08-12T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-secures-645m-deal-for-chinese-dpp-1-inhibitor-in-growing-cross-border-biotech-trend 2025-08-12T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/biotree-s-natural-metabolic-syndrome-drug-ph-100-advances-through-clinical-trials-with-global-partnership 2025-08-12T17:38:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotree-s-natural-metabolic-syndrome-drug-ph-100-advances-through-clinical-trials-with-global-partnership 2025-08-12T17:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/heartflow-raises-364m-in-oversubscribed-ipo-stock-surges-58-on-strong-investor-confidence 2025-08-12T17:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartflow-raises-364m-in-oversubscribed-ipo-stock-surges-58-on-strong-investor-confidence 2025-08-12T17:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/airway-therapeutics-secures-ema-pediatric-approval-for-first-in-class-bpd-prevention-therapy 2025-08-12T17:37:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airway-therapeutics-secures-ema-pediatric-approval-for-first-in-class-bpd-prevention-therapy 2025-08-12T17:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/abcentra-initiates-phase-2b-fortify-trial-for-novel-anti-inflammatory-cardiovascular-therapy-orticumab 2025-08-12T17:37:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abcentra-initiates-phase-2b-fortify-trial-for-novel-anti-inflammatory-cardiovascular-therapy-orticumab 2025-08-12T17:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-expansion-of-aquedeon-s-duett-vascular-graft-system-trial-to-90-patients 2025-08-12T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-expansion-of-aquedeon-s-duett-vascular-graft-system-trial-to-90-patients 2025-08-12T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-sonic-incytes-ai-guided-velacur-one-ultrasound-device-for-chronic-liver-disease-management 2025-08-12T16:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-sonic-incytes-ai-guided-velacur-one-ultrasound-device-for-chronic-liver-disease-management 2025-08-12T16:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-transforms-drug-drug-interaction-prediction-with-85-accuracy-improvement 2025-08-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-transforms-drug-drug-interaction-prediction-with-85-accuracy-improvement 2025-08-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/black-swan-graphene-partners-with-ferro-south-africa-to-expand-graphene-technology-distribution 2025-08-12T14:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/black-swan-graphene-partners-with-ferro-south-africa-to-expand-graphene-technology-distribution 2025-08-12T14:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-secures-us-patent-for-cannabinoid-based-topical-formulation-targeting-skin-conditions 2025-08-12T13:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-secures-us-patent-for-cannabinoid-based-topical-formulation-targeting-skin-conditions 2025-08-12T13:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/vicentra-secures-85m-series-d-to-scale-kaleido-insulin-patch-pump-manufacturing-and-us-market-entry 2025-08-12T13:46:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vicentra-secures-85m-series-d-to-scale-kaleido-insulin-patch-pump-manufacturing-and-us-market-entry 2025-08-12T13:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/xspray-pharma-secures-first-patent-license-deal-with-handa-therapeutics-for-dasatinib-commercialization 2025-08-12T13:44:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xspray-pharma-secures-first-patent-license-deal-with-handa-therapeutics-for-dasatinib-commercialization 2025-08-12T13:44:15+00:00 hourly 0.9 https://trial.medpath.com/news/rakovina-therapeutics-and-nanopalm-form-joint-venture-to-advance-ai-discovered-cancer-drug-kt-3283 2025-08-12T13:42:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rakovina-therapeutics-and-nanopalm-form-joint-venture-to-advance-ai-discovered-cancer-drug-kt-3283 2025-08-12T13:42:43+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-partners-with-kumquat-biosciences-in-1-3-billion-deal-to-develop-kras-g12d-inhibitor-for-hard-to-treat-cancers 2025-08-12T13:42:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-partners-with-kumquat-biosciences-in-1-3-billion-deal-to-develop-kras-g12d-inhibitor-for-hard-to-treat-cancers 2025-08-12T13:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/mabylon-raises-chf-30-million-to-advance-tri-specific-peanut-allergy-antibody-my006-through-phase-i-trials 2025-08-12T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabylon-raises-chf-30-million-to-advance-tri-specific-peanut-allergy-antibody-my006-through-phase-i-trials 2025-08-12T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/fda-allowed-over-150-drugs-from-banned-foreign-factories-to-enter-u-s-market-despite-safety-violations 2025-08-12T13:41:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-allowed-over-150-drugs-from-banned-foreign-factories-to-enter-u-s-market-despite-safety-violations 2025-08-12T13:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-partners-with-sandoz-to-commercialize-ranibizumab-biosimilar-across-multiple-global-markets 2025-08-12T13:40:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-partners-with-sandoz-to-commercialize-ranibizumab-biosimilar-across-multiple-global-markets 2025-08-12T13:40:37+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-padcev-keytruda-combination-shows-significant-survival-benefit-in-muscle-invasive-bladder-cancer-trial 2025-08-12T13:40:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-padcev-keytruda-combination-shows-significant-survival-benefit-in-muscle-invasive-bladder-cancer-trial 2025-08-12T13:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-pharmaceuticals-expands-pipeline-with-453-million-licensing-deal-for-three-novel-peptide-therapeutics 2025-08-12T13:39:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amphastar-pharmaceuticals-expands-pipeline-with-453-million-licensing-deal-for-three-novel-peptide-therapeutics 2025-08-12T13:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/puretech-health-launches-celea-therapeutics-to-advance-phase-3-ready-ipf-treatment 2025-08-12T13:38:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puretech-health-launches-celea-therapeutics-to-advance-phase-3-ready-ipf-treatment 2025-08-12T13:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/panthera-biopartners-secures-major-investment-from-ldc-to-expand-uk-s-largest-clinical-trial-smo-network 2025-08-12T13:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/panthera-biopartners-secures-major-investment-from-ldc-to-expand-uk-s-largest-clinical-trial-smo-network 2025-08-12T13:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-biopharma-files-emergency-motion-to-dea-as-trump-signals-openness-to-medical-cannabis 2025-08-12T09:40:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmj-biopharma-files-emergency-motion-to-dea-as-trump-signals-openness-to-medical-cannabis 2025-08-12T09:40:22+00:00 hourly 0.9 https://trial.medpath.com/news/adze-biotechnology-receives-ethics-approval-for-phase-i-oncolytic-immunotherapy-trial-in-metastatic-melanoma 2025-08-12T09:39:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adze-biotechnology-receives-ethics-approval-for-phase-i-oncolytic-immunotherapy-trial-in-metastatic-melanoma 2025-08-12T09:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-pharma-secures-645-million-global-licensing-deal-for-novel-dpp-1-inhibitor-xh-s004 2025-08-12T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosun-pharma-secures-645-million-global-licensing-deal-for-novel-dpp-1-inhibitor-xh-s004 2025-08-12T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-treatment-disparities-in-high-risk-myelodysplastic-syndrome-patients 2025-08-12T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-treatment-disparities-in-high-risk-myelodysplastic-syndrome-patients 2025-08-12T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/mirum-pharmaceuticals-raises-2025-revenue-guidance-to-490-510-million-following-strong-q2-performance 2025-08-12T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mirum-pharmaceuticals-raises-2025-revenue-guidance-to-490-510-million-following-strong-q2-performance 2025-08-12T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-reports-breakthrough-in-type-1-diabetes-cell-therapy-with-6-month-clinical-data 2025-08-12T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-reports-breakthrough-in-type-1-diabetes-cell-therapy-with-6-month-clinical-data 2025-08-12T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-identify-first-potential-biomarker-for-long-covid-diagnosis 2025-08-11T21:05:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-identify-first-potential-biomarker-for-long-covid-diagnosis 2025-08-11T21:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/india-approves-roche-s-7-minute-subcutaneous-cancer-injection-tecentriq-cutting-treatment-time-by-85 2025-08-11T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-approves-roche-s-7-minute-subcutaneous-cancer-injection-tecentriq-cutting-treatment-time-by-85 2025-08-11T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/garden-launches-bloom-ai-engine-to-accelerate-ip-aware-drug-discovery 2025-08-11T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/garden-launches-bloom-ai-engine-to-accelerate-ip-aware-drug-discovery 2025-08-11T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/early-rhythm-control-therapy-remains-effective-for-atrial-fibrillation-patients-with-obesity-and-diabetes 2025-08-11T21:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/early-rhythm-control-therapy-remains-effective-for-atrial-fibrillation-patients-with-obesity-and-diabetes 2025-08-11T21:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/tahoe-therapeutics-secures-30m-to-create-world-s-largest-single-cell-dataset-for-ai-driven-drug-discovery 2025-08-11T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tahoe-therapeutics-secures-30m-to-create-world-s-largest-single-cell-dataset-for-ai-driven-drug-discovery 2025-08-11T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/veru-selects-novel-modified-release-enobosarm-formulation-for-weight-loss-management-using-advanced-3d-printing-technology 2025-08-11T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veru-selects-novel-modified-release-enobosarm-formulation-for-weight-loss-management-using-advanced-3d-printing-technology 2025-08-11T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/avicanna-secures-u-s-patent-for-topical-cannabinoid-compositions 2025-08-11T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avicanna-secures-u-s-patent-for-topical-cannabinoid-compositions 2025-08-11T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-phase-3-trial-fails-to-meet-primary-endpoints 2025-08-11T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-phase-3-trial-fails-to-meet-primary-endpoints 2025-08-11T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/intermittent-fasting-enhances-anti-androgen-therapy-efficacy-in-prostate-cancer-preclinical-study-shows 2025-08-11T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intermittent-fasting-enhances-anti-androgen-therapy-efficacy-in-prostate-cancer-preclinical-study-shows 2025-08-11T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/inovio-s-ino-3107-dna-medicine-shows-sustained-long-term-benefits-in-recurrent-respiratory-papillomatosis-treatment 2025-08-11T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inovio-s-ino-3107-dna-medicine-shows-sustained-long-term-benefits-in-recurrent-respiratory-papillomatosis-treatment 2025-08-11T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/ankylosing-spondylitis-pipeline-shows-robust-growth-with-20-therapies-in-development 2025-08-11T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ankylosing-spondylitis-pipeline-shows-robust-growth-with-20-therapies-in-development 2025-08-11T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cylembio-plus-pembrolizumab-demonstrates-clinical-improvement-in-advanced-melanoma-phase-3-trial 2025-08-11T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-cylembio-plus-pembrolizumab-demonstrates-clinical-improvement-in-advanced-melanoma-phase-3-trial 2025-08-11T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/subcutaneous-eeg-device-demonstrates-superior-seizure-detection-in-treatment-resistant-epilepsy-study 2025-08-11T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/subcutaneous-eeg-device-demonstrates-superior-seizure-detection-in-treatment-resistant-epilepsy-study 2025-08-11T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-melanoma-vaccine-narrowly-misses-primary-endpoint-in-phase-3-trial-despite-promising-subgroup-results 2025-08-11T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-melanoma-vaccine-narrowly-misses-primary-endpoint-in-phase-3-trial-despite-promising-subgroup-results 2025-08-11T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/sartorius-stedim-biotech-partners-with-nanotein-technologies-to-enhance-cell-therapy-manufacturing-with-nanospark-r-platform 2025-08-11T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sartorius-stedim-biotech-partners-with-nanotein-technologies-to-enhance-cell-therapy-manufacturing-with-nanospark-r-platform 2025-08-11T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/viatris-secures-fda-approval-for-first-generic-iron-sucrose-injection-with-180-day-market-exclusivity 2025-08-11T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viatris-secures-fda-approval-for-first-generic-iron-sucrose-injection-with-180-day-market-exclusivity 2025-08-11T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/inflammation-and-oxidative-stress-drive-osteoporosis-through-disrupted-bone-remodeling 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inflammation-and-oxidative-stress-drive-osteoporosis-through-disrupted-bone-remodeling 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/protac-technology-emerges-as-next-generation-approach-for-ido1-targeted-cancer-immunotherapy 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protac-technology-emerges-as-next-generation-approach-for-ido1-targeted-cancer-immunotherapy 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/compass-therapeutics-reports-promising-clinical-data-across-bispecific-antibody-pipeline 2025-08-11T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/compass-therapeutics-reports-promising-clinical-data-across-bispecific-antibody-pipeline 2025-08-11T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/forx-therapeutics-doses-first-patient-with-novel-parg-inhibitor-forx-428-in-phase-1-cancer-trial 2025-08-11T13:08:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forx-therapeutics-doses-first-patient-with-novel-parg-inhibitor-forx-428-in-phase-1-cancer-trial 2025-08-11T13:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/tango-therapeutics-secures-225-million-in-financing-to-advance-precision-cancer-medicine-pipeline 2025-08-11T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tango-therapeutics-secures-225-million-in-financing-to-advance-precision-cancer-medicine-pipeline 2025-08-11T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/algeria-approves-sino-biopharmaceutical-s-adalimumab-biosimilar-for-autoimmune-disease-treatment 2025-08-11T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/algeria-approves-sino-biopharmaceutical-s-adalimumab-biosimilar-for-autoimmune-disease-treatment 2025-08-11T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/seed-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-rbm39-degrader-st-01156 2025-08-11T12:06:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seed-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-rbm39-degrader-st-01156 2025-08-11T12:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/89bio-reports-q2-2025-results-with-111-5m-net-loss-as-phase-3-mash-and-shtg-trials-advance 2025-08-11T12:05:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/89bio-reports-q2-2025-results-with-111-5m-net-loss-as-phase-3-mash-and-shtg-trials-advance 2025-08-11T12:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/wuxi-biologics-launches-wuxia293stable-platform-to-address-manufacturing-challenges-for-complex-biologics 2025-08-11T12:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wuxi-biologics-launches-wuxia293stable-platform-to-address-manufacturing-challenges-for-complex-biologics 2025-08-11T12:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/kexing-biopharm-partners-with-iqvia-to-accelerate-global-drug-development-and-market-access 2025-08-11T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kexing-biopharm-partners-with-iqvia-to-accelerate-global-drug-development-and-market-access 2025-08-11T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-fda-approval-for-generic-diltiazem-tablets-to-treat-angina-and-hypertension 2025-08-11T12:05:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-fda-approval-for-generic-diltiazem-tablets-to-treat-angina-and-hypertension 2025-08-11T12:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/amphastar-receives-fda-approval-for-generic-iron-sucrose-injection-to-treat-anemia-in-chronic-kidney-disease-patients 2025-08-11T12:04:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amphastar-receives-fda-approval-for-generic-iron-sucrose-injection-to-treat-anemia-in-chronic-kidney-disease-patients 2025-08-11T12:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/kamada-receives-fda-approval-for-houston-plasma-collection-center-expanding-specialty-plasma-operations 2025-08-11T12:04:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kamada-receives-fda-approval-for-houston-plasma-collection-center-expanding-specialty-plasma-operations 2025-08-11T12:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/major-medical-organizations-excluded-from-cdc-vaccine-advisory-workgroups 2025-08-11T12:04:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-medical-organizations-excluded-from-cdc-vaccine-advisory-workgroups 2025-08-11T12:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/cpap-therapy-shows-differential-cardiovascular-effects-based-on-sleep-apnea-risk-profile 2025-08-11T12:02:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cpap-therapy-shows-differential-cardiovascular-effects-based-on-sleep-apnea-risk-profile 2025-08-11T12:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/heart-failure-drug-ivabradine-shows-promise-for-pots-treatment-in-pilot-study 2025-08-11T12:02:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-failure-drug-ivabradine-shows-promise-for-pots-treatment-in-pilot-study 2025-08-11T12:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-star-market-reforms-boost-biotech-financing-as-healthgen-becomes-first-company-to-benefit-from-resumed-rules 2025-08-11T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-star-market-reforms-boost-biotech-financing-as-healthgen-becomes-first-company-to-benefit-from-resumed-rules 2025-08-11T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/ami-pharm-s-ayp-101-enters-phase-3-trial-for-non-inflammatory-fat-reduction 2025-08-11T09:25:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ami-pharm-s-ayp-101-enters-phase-3-trial-for-non-inflammatory-fat-reduction 2025-08-11T09:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-reports-strong-q2-2025-turnaround-with-39-7m-net-income-advances-retinal-disease-pipeline 2025-08-11T09:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-reports-strong-q2-2025-turnaround-with-39-7m-net-income-advances-retinal-disease-pipeline 2025-08-11T09:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/maxwell-biosciences-secures-20m-to-advance-immune-inspired-antimicrobial-platform-through-fda-trials 2025-08-11T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxwell-biosciences-secures-20m-to-advance-immune-inspired-antimicrobial-platform-through-fda-trials 2025-08-11T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/bionxt-solutions-completes-1-25m-oversubscribed-funding-round-to-advance-drug-delivery-platform-development 2025-08-11T05:02:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bionxt-solutions-completes-1-25m-oversubscribed-funding-round-to-advance-drug-delivery-platform-development 2025-08-11T05:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/truemeds-raises-85m-to-expand-generic-drug-platform-serving-india-s-400-million-chronic-patients 2025-08-11T05:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/truemeds-raises-85m-to-expand-generic-drug-platform-serving-india-s-400-million-chronic-patients 2025-08-11T05:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/histoindex-launches-ai-powered-fibrosight-plus-for-enhanced-mash-fibrosis-assessment 2025-08-11T05:00:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/histoindex-launches-ai-powered-fibrosight-plus-for-enhanced-mash-fibrosis-assessment 2025-08-11T05:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/syntara-receives-fda-guidance-for-amsulostat-phase-2-trial-in-myelofibrosis 2025-08-11T05:00:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syntara-receives-fda-guidance-for-amsulostat-phase-2-trial-in-myelofibrosis 2025-08-11T05:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/king-s-college-london-develops-kcl-ho-1i-novel-oral-drug-to-overcome-chemotherapy-resistance 2025-08-11T01:24:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/king-s-college-london-develops-kcl-ho-1i-novel-oral-drug-to-overcome-chemotherapy-resistance 2025-08-11T01:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/lean-body-mass-based-oxaliplatin-dosing-reduces-neuropathy-without-compromising-efficacy-in-stage-iii-colon-cancer 2025-08-10T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lean-body-mass-based-oxaliplatin-dosing-reduces-neuropathy-without-compromising-efficacy-in-stage-iii-colon-cancer 2025-08-10T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/io-biotech-s-cylembio-narrowly-misses-primary-endpoint-in-phase-3-melanoma-trial-despite-progression-free-survival-benefit 2025-08-10T21:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/io-biotech-s-cylembio-narrowly-misses-primary-endpoint-in-phase-3-melanoma-trial-despite-progression-free-survival-benefit 2025-08-10T21:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-advances-tubeless-pivot-insulin-pump-with-october-fda-filing-and-gamified-training-platform 2025-08-10T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modular-medical-advances-tubeless-pivot-insulin-pump-with-october-fda-filing-and-gamified-training-platform 2025-08-10T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-high-volume-intravitreal-injections-do-not-increase-glaucoma-risk 2025-08-10T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-high-volume-intravitreal-injections-do-not-increase-glaucoma-risk 2025-08-10T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/ube2n-emerges-as-novel-prognostic-biomarker-and-therapeutic-target-in-lung-adenocarcinoma 2025-08-10T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ube2n-emerges-as-novel-prognostic-biomarker-and-therapeutic-target-in-lung-adenocarcinoma 2025-08-10T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abiogenesis-clinpharm-receives-regulatory-approval-for-phase-iii-trial-of-phenazopyridine-in-urinary-tract-infections 2025-08-10T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abiogenesis-clinpharm-receives-regulatory-approval-for-phase-iii-trial-of-phenazopyridine-in-urinary-tract-infections 2025-08-10T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/biomarker-analysis-reveals-predictive-factors-for-adjuvant-nivolumab-success-in-muscle-invasive-urothelial-carcinoma 2025-08-10T09:29:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarker-analysis-reveals-predictive-factors-for-adjuvant-nivolumab-success-in-muscle-invasive-urothelial-carcinoma 2025-08-10T09:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/belite-bio-raises-275-million-in-upsized-private-placement-to-advance-retinal-disease-therapies 2025-08-10T09:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belite-bio-raises-275-million-in-upsized-private-placement-to-advance-retinal-disease-therapies 2025-08-10T09:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/avidity-biosciences-reports-strong-q2-results-advances-three-rna-therapeutics-toward-bla-submissions 2025-08-10T05:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avidity-biosciences-reports-strong-q2-results-advances-three-rna-therapeutics-toward-bla-submissions 2025-08-10T05:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/geron-appoints-harout-semerjian-as-ceo-to-drive-rytelo-expansion-and-late-stage-pipeline 2025-08-10T05:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-appoints-harout-semerjian-as-ceo-to-drive-rytelo-expansion-and-late-stage-pipeline 2025-08-10T05:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/us-oncology-enterprise-faces-unprecedented-financial-crisis-as-nci-budget-cuts-threaten-cancer-research-infrastructure 2025-08-10T03:01:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-oncology-enterprise-faces-unprecedented-financial-crisis-as-nci-budget-cuts-threaten-cancer-research-infrastructure 2025-08-10T03:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/novel-multivalent-mrna-vaccines-show-promise-against-mpxv-and-sars-cov-2-in-preclinical-studies 2025-08-10T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-multivalent-mrna-vaccines-show-promise-against-mpxv-and-sars-cov-2-in-preclinical-studies 2025-08-10T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-receives-world-s-first-approval-for-norudca-novel-nafld-treatment 2025-08-10T01:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-receives-world-s-first-approval-for-norudca-novel-nafld-treatment 2025-08-10T01:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-develop-wireless-soft-neural-interface-with-integrated-micropump-for-targeted-brain-drug-delivery 2025-08-10T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-develop-wireless-soft-neural-interface-with-integrated-micropump-for-targeted-brain-drug-delivery 2025-08-10T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/remimazolam-demonstrates-superior-safety-profile-over-propofol-in-icu-bronchoscopy-procedures 2025-08-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remimazolam-demonstrates-superior-safety-profile-over-propofol-in-icu-bronchoscopy-procedures 2025-08-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/janux-therapeutics-receives-10-million-milestone-payment-from-merck-as-first-patient-dosed-in-tractr-cancer-immunotherapy-trial 2025-08-09T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/janux-therapeutics-receives-10-million-milestone-payment-from-merck-as-first-patient-dosed-in-tractr-cancer-immunotherapy-trial 2025-08-09T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/heartflow-s-316-7m-ipo-signals-ai-revolution-in-cardiovascular-diagnostics 2025-08-09T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heartflow-s-316-7m-ipo-signals-ai-revolution-in-cardiovascular-diagnostics 2025-08-09T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/cosmo-pharmaceuticals-and-takeda-renew-multi-year-manufacturing-agreement-for-ulcerative-colitis-treatment 2025-08-09T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cosmo-pharmaceuticals-and-takeda-renew-multi-year-manufacturing-agreement-for-ulcerative-colitis-treatment 2025-08-09T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-first-indigenous-car-t-therapy-achieves-two-year-remission-milestone-in-aggressive-blood-cancer 2025-08-09T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-first-indigenous-car-t-therapy-achieves-two-year-remission-milestone-in-aggressive-blood-cancer 2025-08-09T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-boehringer-ingelheim-s-hernexeos-as-first-in-class-her2-tki-for-rare-lung-cancer-subset 2025-08-09T17:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-boehringer-ingelheim-s-hernexeos-as-first-in-class-her2-tki-for-rare-lung-cancer-subset 2025-08-09T17:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-app-otx-202-reduces-suicide-attempts-by-58-in-high-risk-psychiatric-patients 2025-08-09T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-app-otx-202-reduces-suicide-attempts-by-58-in-high-risk-psychiatric-patients 2025-08-09T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-children-under-5 2025-08-09T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-children-under-5 2025-08-09T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/fda-restricts-bluebird-bio-s-skysona-gene-therapy-following-tripled-cancer-risk 2025-08-09T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-restricts-bluebird-bio-s-skysona-gene-therapy-following-tripled-cancer-risk 2025-08-09T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/sitryx-regains-rights-to-first-in-class-itaconate-mimetic-syx-1042-from-lilly-after-successful-phase-1-trial 2025-08-09T09:30:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sitryx-regains-rights-to-first-in-class-itaconate-mimetic-syx-1042-from-lilly-after-successful-phase-1-trial 2025-08-09T09:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-divests-troubled-new-jersey-plant-while-expanding-global-manufacturing-network 2025-08-09T09:29:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-divests-troubled-new-jersey-plant-while-expanding-global-manufacturing-network 2025-08-09T09:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-advances-phase-3-trial-of-tafenoquine-for-plasmodium-vivax-malaria-treatment-in-india 2025-08-09T09:28:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-advances-phase-3-trial-of-tafenoquine-for-plasmodium-vivax-malaria-treatment-in-india 2025-08-09T09:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/ascendis-pharma-gains-fda-approval-for-skytrofa-in-adult-growth-hormone-deficiency 2025-08-09T09:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ascendis-pharma-gains-fda-approval-for-skytrofa-in-adult-growth-hormone-deficiency 2025-08-09T09:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/oncolytics-biotech-voluntarily-delists-from-toronto-stock-exchange-to-focus-on-u-s-operations 2025-08-09T05:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncolytics-biotech-voluntarily-delists-from-toronto-stock-exchange-to-focus-on-u-s-operations 2025-08-09T05:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/dermarite-industries-recalls-four-otc-products-due-to-life-threatening-burkholderia-cepacia-contamination 2025-08-09T05:30:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermarite-industries-recalls-four-otc-products-due-to-life-threatening-burkholderia-cepacia-contamination 2025-08-09T05:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/atyr-pharma-completes-phase-3-enrollment-for-pulmonary-sarcoidosis-treatment-results-expected-q3-2025 2025-08-09T05:30:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atyr-pharma-completes-phase-3-enrollment-for-pulmonary-sarcoidosis-treatment-results-expected-q3-2025 2025-08-09T05:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-safety-alerts-for-boston-scientific-heart-devices-linked-to-33-deaths 2025-08-09T05:29:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-safety-alerts-for-boston-scientific-heart-devices-linked-to-33-deaths 2025-08-09T05:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-acquires-melinta-therapeutics-for-300-million-to-expand-anti-infective-portfolio 2025-08-09T05:25:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-acquires-melinta-therapeutics-for-300-million-to-expand-anti-infective-portfolio 2025-08-09T05:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/latvian-biotech-cellbox-labs-raises-eur3-3m-to-advance-organ-on-chip-drug-discovery-platform 2025-08-09T05:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/latvian-biotech-cellbox-labs-raises-eur3-3m-to-advance-organ-on-chip-drug-discovery-platform 2025-08-09T05:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/anbio-biotechnology-launches-15-minute-ultra-fast-pcr-system-and-chikungunya-rapid-test-to-combat-global-disease-outbreaks 2025-08-09T05:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anbio-biotechnology-launches-15-minute-ultra-fast-pcr-system-and-chikungunya-rapid-test-to-combat-global-disease-outbreaks 2025-08-09T05:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-initiates-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy-gene-therapy 2025-08-09T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-initiates-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy-gene-therapy 2025-08-09T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-safety-analysis-reveals-complex-toxicity-profile-of-tremelimumab-durvalumab-combination-in-hepatocellular-carcinoma 2025-08-09T01:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-safety-analysis-reveals-complex-toxicity-profile-of-tremelimumab-durvalumab-combination-in-hepatocellular-carcinoma 2025-08-09T01:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/epipen-patent-expiration-on-september-11-2025-set-to-transform-epinephrine-auto-injector-market 2025-08-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epipen-patent-expiration-on-september-11-2025-set-to-transform-epinephrine-auto-injector-market 2025-08-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-stock-plunges-14-amid-legal-challenges-and-leadership-changes 2025-08-09T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-stock-plunges-14-amid-legal-challenges-and-leadership-changes 2025-08-09T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/yale-developed-canine-cancer-vaccine-doubles-survival-rates-in-clinical-trials 2025-08-09T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-developed-canine-cancer-vaccine-doubles-survival-rates-in-clinical-trials 2025-08-09T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/poxel-enters-reorganization-proceedings-as-clinical-stage-biotech-faces-financial-restructuring 2025-08-08T21:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poxel-enters-reorganization-proceedings-as-clinical-stage-biotech-faces-financial-restructuring 2025-08-08T21:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/radella-pharmaceuticals-md-18-demonstrates-2-7-weight-loss-and-cardiometabolic-benefits-in-phase-1b-trial 2025-08-08T21:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radella-pharmaceuticals-md-18-demonstrates-2-7-weight-loss-and-cardiometabolic-benefits-in-phase-1b-trial 2025-08-08T21:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/rbl-secures-investment-from-modi-ventures-to-accelerate-biotech-venture-creation 2025-08-08T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rbl-secures-investment-from-modi-ventures-to-accelerate-biotech-venture-creation 2025-08-08T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/zai-lab-s-dll3-adc-shows-68-response-rate-in-small-cell-lung-cancer-advances-to-global-registrational-study 2025-08-08T21:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zai-lab-s-dll3-adc-shows-68-response-rate-in-small-cell-lung-cancer-advances-to-global-registrational-study 2025-08-08T21:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-delays-zelenectide-pevedotin-regulatory-update-to-q1-2026-amid-multi-agency-consultations 2025-08-08T21:34:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-delays-zelenectide-pevedotin-regulatory-update-to-q1-2026-amid-multi-agency-consultations 2025-08-08T21:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/alector-s-phase-3-ftd-trial-misses-primary-endpoint-despite-fda-endorsed-statistical-plan-amendment 2025-08-08T21:32:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alector-s-phase-3-ftd-trial-misses-primary-endpoint-despite-fda-endorsed-statistical-plan-amendment 2025-08-08T21:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pde4-inhibitor-me3183-demonstrates-significant-efficacy-in-phase-2-plaque-psoriasis-trial 2025-08-08T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pde4-inhibitor-me3183-demonstrates-significant-efficacy-in-phase-2-plaque-psoriasis-trial 2025-08-08T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-researchers-develop-swift-seq-blood-test-to-replace-bone-marrow-biopsies-in-multiple-myeloma 2025-08-08T21:30:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-researchers-develop-swift-seq-blood-test-to-replace-bone-marrow-biopsies-in-multiple-myeloma 2025-08-08T21:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-withdraws-amtagvi-eu-filing-stock-plunges-29-despite-strong-q2-sales 2025-08-08T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-withdraws-amtagvi-eu-filing-stock-plunges-29-despite-strong-q2-sales 2025-08-08T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-hiv-prevention-drug-yeztugo-exceeds-launch-expectations-projected-to-reach-5-billion-by-2031 2025-08-08T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-hiv-prevention-drug-yeztugo-exceeds-launch-expectations-projected-to-reach-5-billion-by-2031 2025-08-08T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/neonc-technologies-receives-fda-authorization-for-phase-ii-brain-cancer-trial-of-neo212 2025-08-08T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neonc-technologies-receives-fda-authorization-for-phase-ii-brain-cancer-trial-of-neo212 2025-08-08T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-secures-extended-patent-protection-for-bexmarilimab-cancer-immunotherapy-through-2040 2025-08-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-secures-extended-patent-protection-for-bexmarilimab-cancer-immunotherapy-through-2040 2025-08-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-therapeutics-extends-cash-runway-to-q4-2026-advances-certepetide-development-through-catalent-partnership 2025-08-08T17:38:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-therapeutics-extends-cash-runway-to-q4-2026-advances-certepetide-development-through-catalent-partnership 2025-08-08T17:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/fosun-s-hlx43-cancer-drug-rights-deal-with-j-j-and-roche-could-generate-hundreds-of-millions-in-strategic-ip-monetization 2025-08-08T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fosun-s-hlx43-cancer-drug-rights-deal-with-j-j-and-roche-could-generate-hundreds-of-millions-in-strategic-ip-monetization 2025-08-08T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-reports-positive-phase-iii-results-for-oral-glp-1-therapy-orforglipron-in-type-2-diabetes-and-obesity 2025-08-08T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-reports-positive-phase-iii-results-for-oral-glp-1-therapy-orforglipron-in-type-2-diabetes-and-obesity 2025-08-08T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/kiora-pharmaceuticals-advances-two-phase-2-retinal-disease-trials-secures-110m-asian-partnership 2025-08-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kiora-pharmaceuticals-advances-two-phase-2-retinal-disease-trials-secures-110m-asian-partnership 2025-08-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-therapy-shows-unprecedented-promise-as-potential-cure-for-lupus-in-early-clinical-trials 2025-08-08T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-therapy-shows-unprecedented-promise-as-potential-cure-for-lupus-in-early-clinical-trials 2025-08-08T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-receives-florida-regulatory-approval-for-dura-medical-acquisition-to-expand-precision-psychiatry-network 2025-08-08T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-therapeutics-receives-florida-regulatory-approval-for-dura-medical-acquisition-to-expand-precision-psychiatry-network 2025-08-08T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-implements-major-restructuring-amid-regulatory-setbacks-and-commercial-challenges 2025-08-08T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-implements-major-restructuring-amid-regulatory-setbacks-and-commercial-challenges 2025-08-08T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/wcc-biomedical-advances-microneedle-drug-delivery-platform-with-winmap-technology-at-nacds-expo 2025-08-08T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wcc-biomedical-advances-microneedle-drug-delivery-platform-with-winmap-technology-at-nacds-expo 2025-08-08T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-s-epkinly-achieves-79-reduction-in-disease-progression-risk-in-phase-iii-follicular-lymphoma-trial 2025-08-08T17:32:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-s-epkinly-achieves-79-reduction-in-disease-progression-risk-in-phase-iii-follicular-lymphoma-trial 2025-08-08T17:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/capivasertib-causes-distinctive-glucose-spikes-in-breast-cancer-patient-prompting-japanese-safety-warning 2025-08-08T13:25:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capivasertib-causes-distinctive-glucose-spikes-in-breast-cancer-patient-prompting-japanese-safety-warning 2025-08-08T13:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/roswell-park-researchers-develop-first-genomic-tool-to-guide-kidney-cancer-immunotherapy-decisions 2025-08-08T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roswell-park-researchers-develop-first-genomic-tool-to-guide-kidney-cancer-immunotherapy-decisions 2025-08-08T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/codex-genetics-partners-with-pacific-edge-to-bring-non-invasive-bladder-cancer-testing-to-hong-kong 2025-08-08T13:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/codex-genetics-partners-with-pacific-edge-to-bring-non-invasive-bladder-cancer-testing-to-hong-kong 2025-08-08T13:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/remegen-receives-fda-clearance-for-phase-ii-trial-of-bispecific-antibody-rc148-in-advanced-solid-tumors 2025-08-08T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remegen-receives-fda-clearance-for-phase-ii-trial-of-bispecific-antibody-rc148-in-advanced-solid-tumors 2025-08-08T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/orchestra-biomed-expands-backbeat-hypertension-trial-eligibility-24-fold-following-fda-protocol-approval 2025-08-08T13:23:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orchestra-biomed-expands-backbeat-hypertension-trial-eligibility-24-fold-following-fda-protocol-approval 2025-08-08T13:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/10x-genomics-acquires-scale-biosciences-to-expand-single-cell-analysis-capabilities 2025-08-08T09:37:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10x-genomics-acquires-scale-biosciences-to-expand-single-cell-analysis-capabilities 2025-08-08T09:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-reports-promising-preclinical-data-for-nimacimab-as-obesity-treatment-ahead-of-phase-2a-results 2025-08-08T09:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skye-bioscience-reports-promising-preclinical-data-for-nimacimab-as-obesity-treatment-ahead-of-phase-2a-results 2025-08-08T09:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-launches-fda-cleared-preeclampsia-testing-service-with-potential-10-million-cost-savings 2025-08-08T09:31:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-launches-fda-cleared-preeclampsia-testing-service-with-potential-10-million-cost-savings 2025-08-08T09:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-secures-370-million-settlement-and-future-royalties-in-curevac-biontech-mrna-patent-dispute 2025-08-08T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-secures-370-million-settlement-and-future-royalties-in-curevac-biontech-mrna-patent-dispute 2025-08-08T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/smart-hydrogel-achieves-90-diabetic-wound-closure-in-12-days-through-novel-mirna-therapy 2025-08-08T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/smart-hydrogel-achieves-90-diabetic-wound-closure-in-12-days-through-novel-mirna-therapy 2025-08-08T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/89bio-advances-phase-3-trials-for-pegozafermin-in-mash-and-severe-hypertriglyceridemia-with-561m-cash-position 2025-08-08T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/89bio-advances-phase-3-trials-for-pegozafermin-in-mash-and-severe-hypertriglyceridemia-with-561m-cash-position 2025-08-08T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/dewpoint-therapeutics-cuts-70-of-workforce-refocuses-on-lead-cancer-drug-dptx3186 2025-08-08T09:24:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dewpoint-therapeutics-cuts-70-of-workforce-refocuses-on-lead-cancer-drug-dptx3186 2025-08-08T09:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/kura-oncology-s-ziftomenib-receives-fda-priority-review-for-npm1-mutant-aml-pdufa-date-set-for-november-2025 2025-08-08T05:37:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kura-oncology-s-ziftomenib-receives-fda-priority-review-for-npm1-mutant-aml-pdufa-date-set-for-november-2025 2025-08-08T05:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/progressive-supranuclear-palsy-market-poised-for-growth-as-emerging-therapies-advance-through-clinical-trials 2025-08-08T05:36:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/progressive-supranuclear-palsy-market-poised-for-growth-as-emerging-therapies-advance-through-clinical-trials 2025-08-08T05:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/newcastle-study-shows-safe-withdrawal-of-eculizumab-in-rare-kidney-disease-saving-nhs-ps4-2-million-per-patient 2025-08-08T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newcastle-study-shows-safe-withdrawal-of-eculizumab-in-rare-kidney-disease-saving-nhs-ps4-2-million-per-patient 2025-08-08T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/retension-pharmaceuticals-secures-15m-series-b-to-advance-novel-hypertension-drug-rtn-001-into-phase-2b-trial 2025-08-08T05:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/retension-pharmaceuticals-secures-15m-series-b-to-advance-novel-hypertension-drug-rtn-001-into-phase-2b-trial 2025-08-08T05:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/insulin-access-disparities-persist-despite-cost-stabilization-study-reveals-long-term-health-system-burden 2025-08-08T03:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulin-access-disparities-persist-despite-cost-stabilization-study-reveals-long-term-health-system-burden 2025-08-08T03:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/infectious-disease-screening-in-substance-use-treatment-programs-shows-dramatic-increases-in-detection-and-prevention 2025-08-08T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infectious-disease-screening-in-substance-use-treatment-programs-shows-dramatic-increases-in-detection-and-prevention 2025-08-08T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-supply-chains-face-new-challenges-from-tariffs-and-ai-disruption 2025-08-08T03:31:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-supply-chains-face-new-challenges-from-tariffs-and-ai-disruption 2025-08-08T03:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-reports-strong-q2-2025-results-pivots-strategy-to-focus-on-cancer-care-continuum 2025-08-08T03:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-reports-strong-q2-2025-results-pivots-strategy-to-focus-on-cancer-care-continuum 2025-08-08T03:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/genetic-testing-reduces-severe-chemotherapy-side-effects-by-42-in-gastrointestinal-cancer-patients 2025-08-08T01:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genetic-testing-reduces-severe-chemotherapy-side-effects-by-42-in-gastrointestinal-cancer-patients 2025-08-08T01:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/relay-therapeutics-advances-rly-2608-to-phase-3-trial-with-promising-breast-cancer-data 2025-08-08T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relay-therapeutics-advances-rly-2608-to-phase-3-trial-with-promising-breast-cancer-data 2025-08-08T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/biomendics-launches-tames-02-trial-for-first-in-class-eb-simplex-therapy-tolasure 2025-08-08T01:36:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomendics-launches-tames-02-trial-for-first-in-class-eb-simplex-therapy-tolasure 2025-08-08T01:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-appoints-joseph-hulihan-as-chief-medical-officer-to-lead-simufilam-development-for-tsc-related-epilepsy 2025-08-08T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassava-sciences-appoints-joseph-hulihan-as-chief-medical-officer-to-lead-simufilam-development-for-tsc-related-epilepsy 2025-08-08T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/arcellx-reports-strong-car-t-clinical-data-despite-72-revenue-drop-in-q2-2025 2025-08-08T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcellx-reports-strong-car-t-clinical-data-despite-72-revenue-drop-in-q2-2025 2025-08-08T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-evidence-validates-bispecific-antibodies-as-effective-treatment-option-in-relapsed-refractory-multiple-myeloma 2025-08-08T01:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-evidence-validates-bispecific-antibodies-as-effective-treatment-option-in-relapsed-refractory-multiple-myeloma 2025-08-08T01:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2025-08-08T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2025-08-08T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/ignite-proteomics-partners-with-vanderbilt-to-advance-breast-cancer-immunotherapy-biomarker-discovery 2025-08-08T01:31:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ignite-proteomics-partners-with-vanderbilt-to-advance-breast-cancer-immunotherapy-biomarker-discovery 2025-08-08T01:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/fibrogen-receives-fda-approval-for-phase-3-trial-of-roxadustat-in-lower-risk-mds-patients-with-high-transfusion-burden 2025-08-08T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fibrogen-receives-fda-approval-for-phase-3-trial-of-roxadustat-in-lower-risk-mds-patients-with-high-transfusion-burden 2025-08-08T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-reports-strong-q2-2025-results-with-60m-revenue-as-amtagvi-adoption-accelerates 2025-08-08T01:29:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-reports-strong-q2-2025-results-with-60m-revenue-as-amtagvi-adoption-accelerates 2025-08-08T01:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/daxor-receives-fda-clearance-for-next-generation-blood-volume-analyzer-with-3x-faster-analysis 2025-08-08T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/daxor-receives-fda-clearance-for-next-generation-blood-volume-analyzer-with-3x-faster-analysis 2025-08-08T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/annexon-s-vonaprument-selected-for-ema-s-product-development-coordinator-pilot-program-for-dry-amd-treatment 2025-08-08T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annexon-s-vonaprument-selected-for-ema-s-product-development-coordinator-pilot-program-for-dry-amd-treatment 2025-08-08T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-liquid-embolic-system-for-hypervascular-tumor-treatment 2025-08-08T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-liquid-embolic-system-for-hypervascular-tumor-treatment 2025-08-08T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/sequence-lifescience-receives-irb-approval-for-novel-matched-controls-trial-in-diabetic-foot-ulcers 2025-08-08T01:27:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sequence-lifescience-receives-irb-approval-for-novel-matched-controls-trial-in-diabetic-foot-ulcers 2025-08-08T01:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/triple-combination-therapy-shows-promise-for-ruxolitinib-resistant-myelofibrosis-patient 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-combination-therapy-shows-promise-for-ruxolitinib-resistant-myelofibrosis-patient 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-phase-2b-hiv-trial 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-phase-2b-hiv-trial 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sellas-life-sciences-receives-positive-idmc-recommendation-to-continue-phase-3-regal-trial-of-galinpepimut-s-in-aml 2025-08-07T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sellas-life-sciences-receives-positive-idmc-recommendation-to-continue-phase-3-regal-trial-of-galinpepimut-s-in-aml 2025-08-07T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-pkids-trial-challenges-standard-pediatric-kidney-stone-treatment-approaches 2025-08-07T21:41:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-pkids-trial-challenges-standard-pediatric-kidney-stone-treatment-approaches 2025-08-07T21:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/faers-database-analysis-reveals-safety-profile-of-imiglucerase-in-gaucher-disease-treatment 2025-08-07T21:39:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faers-database-analysis-reveals-safety-profile-of-imiglucerase-in-gaucher-disease-treatment 2025-08-07T21:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/quince-therapeutics-partners-with-option-care-health-to-streamline-edsp-commercialization-for-rare-disease-treatment 2025-08-07T21:39:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quince-therapeutics-partners-with-option-care-health-to-streamline-edsp-commercialization-for-rare-disease-treatment 2025-08-07T21:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-complete-response-letter-for-replimune-s-rp1-oncolytic-immunotherapy-delaying-melanoma-launch 2025-08-07T21:37:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-complete-response-letter-for-replimune-s-rp1-oncolytic-immunotherapy-delaying-melanoma-launch 2025-08-07T21:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/strand-therapeutics-raises-153m-series-b-to-advance-programmable-mrna-cancer-therapies 2025-08-07T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strand-therapeutics-raises-153m-series-b-to-advance-programmable-mrna-cancer-therapies 2025-08-07T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-cachexia-pipeline-shows-promise-with-20-therapies-in-development-across-multiple-companies 2025-08-07T21:35:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-cachexia-pipeline-shows-promise-with-20-therapies-in-development-across-multiple-companies 2025-08-07T21:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/dulaglutide-biosimilar-ly05008-demonstrates-therapeutic-equivalence-in-phase-3-trial-for-type-2-diabetes 2025-08-07T21:35:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dulaglutide-biosimilar-ly05008-demonstrates-therapeutic-equivalence-in-phase-3-trial-for-type-2-diabetes 2025-08-07T21:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/cardiol-therapeutics-stock-plunges-20-as-cbd-based-cardiolrx-misses-primary-endpoints-in-myocarditis-trial 2025-08-07T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardiol-therapeutics-stock-plunges-20-as-cbd-based-cardiolrx-misses-primary-endpoints-in-myocarditis-trial 2025-08-07T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/avobis-bio-seeks-fda-fast-track-status-for-implantable-cell-therapy-following-positive-crohn-s-fistula-trial 2025-08-07T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avobis-bio-seeks-fda-fast-track-status-for-implantable-cell-therapy-following-positive-crohn-s-fistula-trial 2025-08-07T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approved-asthma-drug-zileuton-shows-promise-in-preventing-food-allergy-reactions 2025-08-07T21:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approved-asthma-drug-zileuton-shows-promise-in-preventing-food-allergy-reactions 2025-08-07T21:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/sanome-s-ai-platform-memori-receives-class-iib-ce-certification-for-early-healthcare-associated-infection-detection 2025-08-07T21:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanome-s-ai-platform-memori-receives-class-iib-ce-certification-for-early-healthcare-associated-infection-detection 2025-08-07T21:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/brightwater-research-prepares-clinical-trials-for-anti-metastatic-lung-cancer-drug-valoxydin 2025-08-07T21:32:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brightwater-research-prepares-clinical-trials-for-anti-metastatic-lung-cancer-drug-valoxydin 2025-08-07T21:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/nccn-updates-small-cell-lung-cancer-guidelines-to-include-lambert-eaton-myasthenic-syndrome-testing-and-treatment 2025-08-07T17:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nccn-updates-small-cell-lung-cancer-guidelines-to-include-lambert-eaton-myasthenic-syndrome-testing-and-treatment 2025-08-07T17:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/annovis-bio-secures-comprehensive-patent-protection-for-crystal-buntanetap-through-2046 2025-08-07T17:39:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/annovis-bio-secures-comprehensive-patent-protection-for-crystal-buntanetap-through-2046 2025-08-07T17:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/tegoprazan-demonstrates-superior-long-term-gerd-management-in-phase-3-triumph-study 2025-08-07T17:38:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tegoprazan-demonstrates-superior-long-term-gerd-management-in-phase-3-triumph-study 2025-08-07T17:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ajovy-as-first-cgrp-antagonist-for-pediatric-migraine-prevention 2025-08-07T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ajovy-as-first-cgrp-antagonist-for-pediatric-migraine-prevention 2025-08-07T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-optional-storage-instructions-don-t-induce-patent-infringement-in-generic-drug-case 2025-08-07T17:38:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-optional-storage-instructions-don-t-induce-patent-infringement-in-generic-drug-case 2025-08-07T17:38:08+00:00 hourly 0.9 https://trial.medpath.com/news/iovance-biotherapeutics-cuts-workforce-by-nearly-20-following-slow-amtagvi-cell-therapy-launch 2025-08-07T17:37:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iovance-biotherapeutics-cuts-workforce-by-nearly-20-following-slow-amtagvi-cell-therapy-launch 2025-08-07T17:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/maxona-pharmaceuticals-submits-ind-application-for-max-001-novel-non-opioid-pain-treatment 2025-08-07T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maxona-pharmaceuticals-submits-ind-application-for-max-001-novel-non-opioid-pain-treatment 2025-08-07T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/nice-recommends-first-nhs-treatment-for-rare-eye-disease-lhon-ending-access-disparity-in-england 2025-08-07T17:37:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-recommends-first-nhs-treatment-for-rare-eye-disease-lhon-ending-access-disparity-in-england 2025-08-07T17:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/alexion-secures-canadian-access-agreement-for-ultomiris-in-two-rare-autoimmune-diseases 2025-08-07T17:37:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alexion-secures-canadian-access-agreement-for-ultomiris-in-two-rare-autoimmune-diseases 2025-08-07T17:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/intas-pharmaceuticals-and-accord-biopharma-acquire-udenyca-biosimilar-expanding-global-pegfilgrastim-market-presence 2025-08-07T17:36:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intas-pharmaceuticals-and-accord-biopharma-acquire-udenyca-biosimilar-expanding-global-pegfilgrastim-market-presence 2025-08-07T17:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-confirms-tamiflu-safety-in-children-debunks-neuropsychiatric-risk-concerns 2025-08-07T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-confirms-tamiflu-safety-in-children-debunks-neuropsychiatric-risk-concerns 2025-08-07T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/apreo-health-raises-130-million-to-advance-pivotal-trial-for-novel-emphysema-device 2025-08-07T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apreo-health-raises-130-million-to-advance-pivotal-trial-for-novel-emphysema-device 2025-08-07T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/ph-responsive-graphene-nanomaterials-achieve-enhanced-tumor-targeting-in-breakthrough-cancer-drug-delivery-study 2025-08-07T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ph-responsive-graphene-nanomaterials-achieve-enhanced-tumor-targeting-in-breakthrough-cancer-drug-delivery-study 2025-08-07T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-launches-clinical-trials-for-haystack-mrd-ctdna-test-in-head-and-neck-and-skin-cancers 2025-08-07T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-launches-clinical-trials-for-haystack-mrd-ctdna-test-in-head-and-neck-and-skin-cancers 2025-08-07T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/meta-analysis-confirms-epimedium-s-efficacy-in-primary-osteoporosis-treatment 2025-08-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/meta-analysis-confirms-epimedium-s-efficacy-in-primary-osteoporosis-treatment 2025-08-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/faron-pharmaceuticals-reports-43-complete-remission-rate-in-high-risk-myelodysplastic-syndrome-trial 2025-08-07T13:29:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/faron-pharmaceuticals-reports-43-complete-remission-rate-in-high-risk-myelodysplastic-syndrome-trial 2025-08-07T13:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/minghui-pharmaceutical-secures-131-million-pre-ipo-funding-to-advance-oncology-pipeline-and-commercial-launch 2025-08-07T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minghui-pharmaceutical-secures-131-million-pre-ipo-funding-to-advance-oncology-pipeline-and-commercial-launch 2025-08-07T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-gene-therapy-ga001-shows-promise-in-restoring-vision-for-retinitis-pigmentosa-patients 2025-08-07T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-gene-therapy-ga001-shows-promise-in-restoring-vision-for-retinitis-pigmentosa-patients 2025-08-07T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-advances-gene-therapy-to-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy 2025-08-07T13:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-advances-gene-therapy-to-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy 2025-08-07T13:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/valneva-overcomes-fda-safety-pause-for-ixchiq-chikungunya-vaccine-strengthens-market-position 2025-08-07T13:27:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valneva-overcomes-fda-safety-pause-for-ixchiq-chikungunya-vaccine-strengthens-market-position 2025-08-07T13:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/sinomed-s-cometiu-stent-system-faces-regulatory-setback-in-china-despite-fda-breakthrough-designation 2025-08-07T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sinomed-s-cometiu-stent-system-faces-regulatory-setback-in-china-despite-fda-breakthrough-designation 2025-08-07T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/fujifilm-and-horiba-develop-revolutionary-gene-delivery-system-with-100x-productivity-boost-for-gene-therapy-manufacturing 2025-08-07T09:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fujifilm-and-horiba-develop-revolutionary-gene-delivery-system-with-100x-productivity-boost-for-gene-therapy-manufacturing 2025-08-07T09:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-and-absci-expand-ai-drug-discovery-partnership-with-second-dermatology-target 2025-08-07T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/almirall-and-absci-expand-ai-drug-discovery-partnership-with-second-dermatology-target 2025-08-07T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/expert-highlights-optimal-positioning-of-bispecific-t-cell-engagers-in-multiple-myeloma-treatment 2025-08-07T09:24:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-highlights-optimal-positioning-of-bispecific-t-cell-engagers-in-multiple-myeloma-treatment 2025-08-07T09:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/modular-medical-completes-clinical-study-of-modd1-insulin-pump-prepares-for-next-generation-pivot-launch 2025-08-07T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modular-medical-completes-clinical-study-of-modd1-insulin-pump-prepares-for-next-generation-pivot-launch 2025-08-07T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/cartherics-opens-advanced-cell-therapy-manufacturing-facility-to-support-cth-401-clinical-development 2025-08-07T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cartherics-opens-advanced-cell-therapy-manufacturing-facility-to-support-cth-401-clinical-development 2025-08-07T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/voyager-therapeutics-advances-single-dose-aav-gene-therapy-vy-1706-for-alzheimer-s-disease-targeting-ind-filing-in-2026 2025-08-07T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voyager-therapeutics-advances-single-dose-aav-gene-therapy-vy-1706-for-alzheimer-s-disease-targeting-ind-filing-in-2026 2025-08-07T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/blood-based-protein-analysis-achieves-85-8-accuracy-in-predicting-triple-negative-breast-cancer-immunotherapy-response 2025-08-07T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-based-protein-analysis-achieves-85-8-accuracy-in-predicting-triple-negative-breast-cancer-immunotherapy-response 2025-08-07T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/day-one-biopharmaceuticals-reports-310-revenue-surge-for-pediatric-cancer-drug-ojemda 2025-08-07T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/day-one-biopharmaceuticals-reports-310-revenue-surge-for-pediatric-cancer-drug-ojemda 2025-08-07T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/precision-biosciences-reports-first-clinical-evidence-of-hepatitis-b-gene-editing-therapy-pbgene-hbv 2025-08-07T01:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-biosciences-reports-first-clinical-evidence-of-hepatitis-b-gene-editing-therapy-pbgene-hbv 2025-08-07T01:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/lonza-excellos-and-akadeum-form-strategic-alliance-to-transform-cell-therapy-manufacturing-quality 2025-08-07T01:29:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lonza-excellos-and-akadeum-form-strategic-alliance-to-transform-cell-therapy-manufacturing-quality 2025-08-07T01:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-therapeutics-files-first-nda-for-icotrokinra-in-psoriasis-advances-rusfertide-for-polycythemia-vera 2025-08-07T01:29:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-therapeutics-files-first-nda-for-icotrokinra-in-psoriasis-advances-rusfertide-for-polycythemia-vera 2025-08-07T01:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/chai-discovery-raises-70m-series-a-to-revolutionize-antibody-design-with-ai-platform-achieving-20-hit-rate 2025-08-07T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chai-discovery-raises-70m-series-a-to-revolutionize-antibody-design-with-ai-platform-achieving-20-hit-rate 2025-08-07T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-nestacell-r-dental-pulp-stem-cell-therapy-significantly-improves-motor-function-in-huntington-s-disease-patients 2025-08-07T01:29:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-nestacell-r-dental-pulp-stem-cell-therapy-significantly-improves-motor-function-in-huntington-s-disease-patients 2025-08-07T01:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/henlius-initiates-phase-2-trial-of-first-in-class-sialidase-therapy-hlx79-combined-with-rituximab-for-glomerulonephritis 2025-08-07T01:28:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/henlius-initiates-phase-2-trial-of-first-in-class-sialidase-therapy-hlx79-combined-with-rituximab-for-glomerulonephritis 2025-08-07T01:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-blocks-edwards-lifesciences-945m-jenavalve-acquisition-over-tavr-ar-device-competition-concerns 2025-08-07T01:27:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-blocks-edwards-lifesciences-945m-jenavalve-acquisition-over-tavr-ar-device-competition-concerns 2025-08-07T01:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nanoparticle-therapy-agg-clnp-shows-promise-for-preventing-rheumatoid-arthritis-and-reducing-flares 2025-08-06T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nanoparticle-therapy-agg-clnp-shows-promise-for-preventing-rheumatoid-arthritis-and-reducing-flares 2025-08-06T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/cardurion-completes-enrollment-in-phase-2-trials-for-novel-heart-failure-drug-crd-750 2025-08-06T21:37:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cardurion-completes-enrollment-in-phase-2-trials-for-novel-heart-failure-drug-crd-750 2025-08-06T21:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/renovorx-reports-strong-q2-2025-commercial-growth-and-positive-phase-iii-trial-continuation 2025-08-06T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renovorx-reports-strong-q2-2025-commercial-growth-and-positive-phase-iii-trial-continuation 2025-08-06T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/therabene-appoints-dr-oscar-kashala-as-cmo-to-advance-protein-degrader-pipeline-for-hard-to-treat-cancers 2025-08-06T21:35:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/therabene-appoints-dr-oscar-kashala-as-cmo-to-advance-protein-degrader-pipeline-for-hard-to-treat-cancers 2025-08-06T21:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/phase-i-trial-establishes-maximum-tolerated-dose-for-pegylated-liposomal-doxorubicin-plus-ifosfamide-in-advanced-soft-tissue-sarcoma 2025-08-06T21:33:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-i-trial-establishes-maximum-tolerated-dose-for-pegylated-liposomal-doxorubicin-plus-ifosfamide-in-advanced-soft-tissue-sarcoma 2025-08-06T21:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-advances-coramitug-to-phase-3-for-attr-cardiomyopathy-following-successful-phase-2-trial 2025-08-06T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-advances-coramitug-to-phase-3-for-attr-cardiomyopathy-following-successful-phase-2-trial 2025-08-06T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/dual-clinical-trials-advance-mesothelioma-treatment-with-novel-immunotherapy-combinations 2025-08-06T21:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-clinical-trials-advance-mesothelioma-treatment-with-novel-immunotherapy-combinations 2025-08-06T21:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-first-accelerated-approval-for-h3-k27m-mutated-diffuse-midline-glioma-with-dordaviprone 2025-08-06T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-first-accelerated-approval-for-h3-k27m-mutated-diffuse-midline-glioma-with-dordaviprone 2025-08-06T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/harvard-study-reveals-lithium-deficiency-as-potential-driver-of-alzheimer-s-disease 2025-08-06T17:46:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harvard-study-reveals-lithium-deficiency-as-potential-driver-of-alzheimer-s-disease 2025-08-06T17:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/astria-therapeutics-secures-16-million-japan-partnership-for-hereditary-angioedema-treatment-navenibart 2025-08-06T17:41:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astria-therapeutics-secures-16-million-japan-partnership-for-hereditary-angioedema-treatment-navenibart 2025-08-06T17:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/mark-cuban-s-cost-plus-drugs-expands-pharmacy-network-through-giant-eagle-partnership 2025-08-06T17:41:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mark-cuban-s-cost-plus-drugs-expands-pharmacy-network-through-giant-eagle-partnership 2025-08-06T17:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-s-hmbd-002-shows-promise-against-triple-negative-breast-cancer-in-preclinical-studies 2025-08-06T17:40:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-s-hmbd-002-shows-promise-against-triple-negative-breast-cancer-in-preclinical-studies 2025-08-06T17:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/polyactiva-initiates-us-phase-2b-trial-for-six-month-biodegradable-glaucoma-implant-pa5108 2025-08-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyactiva-initiates-us-phase-2b-trial-for-six-month-biodegradable-glaucoma-implant-pa5108 2025-08-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/insmed-reports-strong-q2-2025-results-with-arikayce-growth-and-brensocatib-approval-pending 2025-08-06T17:39:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insmed-reports-strong-q2-2025-results-with-arikayce-growth-and-brensocatib-approval-pending 2025-08-06T17:39:52+00:00 hourly 0.9 https://trial.medpath.com/news/experimental-dendritic-cell-therapy-shows-promise-for-glioblastoma-in-phase-1-trial 2025-08-06T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experimental-dendritic-cell-therapy-shows-promise-for-glioblastoma-in-phase-1-trial 2025-08-06T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/diamedica-therapeutics-appoints-julie-krop-as-chief-medical-officer-to-advance-dm199-development 2025-08-06T17:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamedica-therapeutics-appoints-julie-krop-as-chief-medical-officer-to-advance-dm199-development 2025-08-06T17:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/standard-biotools-somascan-platform-selected-for-singapore-s-landmark-100000-sample-precision-medicine-study 2025-08-06T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/standard-biotools-somascan-platform-selected-for-singapore-s-landmark-100000-sample-precision-medicine-study 2025-08-06T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/samson-clinical-initiates-phase-iii-trial-of-sublingual-minoxidil-for-male-pattern-hair-loss 2025-08-06T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samson-clinical-initiates-phase-iii-trial-of-sublingual-minoxidil-for-male-pattern-hair-loss 2025-08-06T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-birelentinib-for-relapsed-refractory-cll-sll 2025-08-06T17:37:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-birelentinib-for-relapsed-refractory-cll-sll 2025-08-06T17:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/revvity-launches-phsense-reagents-to-accelerate-gpcr-and-adc-drug-development 2025-08-06T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revvity-launches-phsense-reagents-to-accelerate-gpcr-and-adc-drug-development 2025-08-06T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-boston-children-s-hospital-and-broad-clinical-labs-launch-brightseq-initiative-for-pediatric-cancer-genomics 2025-08-06T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-boston-children-s-hospital-and-broad-clinical-labs-launch-brightseq-initiative-for-pediatric-cancer-genomics 2025-08-06T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tocilizumab-anoh-biosimilar-for-cytokine-release-syndrome-treatment 2025-08-06T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tocilizumab-anoh-biosimilar-for-cytokine-release-syndrome-treatment 2025-08-06T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/oxaliplatin-shows-survival-benefit-only-in-stage-iii-colorectal-cancer-patients-under-70-years 2025-08-06T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxaliplatin-shows-survival-benefit-only-in-stage-iii-colorectal-cancer-patients-under-70-years 2025-08-06T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/jama-surgery-study-validates-dex-g2-blood-test-for-early-gastric-cancer-detection-with-95-sensitivity 2025-08-06T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jama-surgery-study-validates-dex-g2-blood-test-for-early-gastric-cancer-detection-with-95-sensitivity 2025-08-06T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/lantheus-secures-fda-acceptance-for-enhanced-psma-pet-imaging-agent-with-50-increased-batch-size 2025-08-06T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lantheus-secures-fda-acceptance-for-enhanced-psma-pet-imaging-agent-with-50-increased-batch-size 2025-08-06T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/mannkind-secures-500-million-strategic-financing-from-blackstone-to-advance-inhaled-therapeutics-pipeline 2025-08-06T13:25:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mannkind-secures-500-million-strategic-financing-from-blackstone-to-advance-inhaled-therapeutics-pipeline 2025-08-06T13:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/novel-nmda-receptor-modulator-onfasprodil-shows-rapid-antidepressant-effects-with-reduced-side-effects-in-phase-2-trial 2025-08-06T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-nmda-receptor-modulator-onfasprodil-shows-rapid-antidepressant-effects-with-reduced-side-effects-in-phase-2-trial 2025-08-06T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/two-versus-three-cycles-of-induction-chemotherapy-show-similar-survival-outcomes-in-advanced-nasopharyngeal-carcinoma 2025-08-06T13:25:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-versus-three-cycles-of-induction-chemotherapy-show-similar-survival-outcomes-in-advanced-nasopharyngeal-carcinoma 2025-08-06T13:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/two-major-trials-show-egfr-inhibitors-fail-to-improve-outcomes-in-head-and-neck-cancer 2025-08-06T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/two-major-trials-show-egfr-inhibitors-fail-to-improve-outcomes-in-head-and-neck-cancer 2025-08-06T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/cognitive-functional-therapy-shows-sustained-benefits-for-chronic-low-back-pain-after-three-years 2025-08-06T13:24:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognitive-functional-therapy-shows-sustained-benefits-for-chronic-low-back-pain-after-three-years 2025-08-06T13:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/biontech-establishes-clinical-trial-platform-in-victoria-to-accelerate-cancer-treatment-access 2025-08-06T13:24:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biontech-establishes-clinical-trial-platform-in-victoria-to-accelerate-cancer-treatment-access 2025-08-06T13:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/immunoprecise-antibodies-divests-netherlands-operations-for-12m-to-focus-on-ai-driven-drug-discovery-platform 2025-08-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunoprecise-antibodies-divests-netherlands-operations-for-12m-to-focus-on-ai-driven-drug-discovery-platform 2025-08-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-regulation-of-cues-therapy-shows-20-greater-efficacy-than-standard-treatment-for-binge-eating-disorder-in-veterans 2025-08-06T09:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-regulation-of-cues-therapy-shows-20-greater-efficacy-than-standard-treatment-for-binge-eating-disorder-in-veterans 2025-08-06T09:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-receives-fda-rmat-designation-for-car-t-therapy-glpg5101-in-relapsed-refractory-mantle-cell-lymphoma 2025-08-06T09:28:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-receives-fda-rmat-designation-for-car-t-therapy-glpg5101-in-relapsed-refractory-mantle-cell-lymphoma 2025-08-06T09:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/ainnova-tech-revises-clinical-trial-protocol-for-ai-based-diabetic-retinopathy-detection-following-fda-feedback 2025-08-06T09:28:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ainnova-tech-revises-clinical-trial-protocol-for-ai-based-diabetic-retinopathy-detection-following-fda-feedback 2025-08-06T09:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/new-zealand-s-fast-track-approvals-act-faces-early-implementation-challenges-as-rejection-rates-rise 2025-08-06T09:28:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-zealand-s-fast-track-approvals-act-faces-early-implementation-challenges-as-rejection-rates-rise 2025-08-06T09:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-medical-technology-companies-launch-clinical-trials-for-revolutionary-ct-imaging-systems-in-shanghai 2025-08-06T09:27:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-medical-technology-companies-launch-clinical-trials-for-revolutionary-ct-imaging-systems-in-shanghai 2025-08-06T09:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/membrane-tethered-slp-76-engineering-overcomes-car-t-cell-limitations-against-low-antigen-tumors 2025-08-06T05:22:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/membrane-tethered-slp-76-engineering-overcomes-car-t-cell-limitations-against-low-antigen-tumors 2025-08-06T05:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/bracco-imaging-receives-nmpa-approval-for-sonovue-in-female-infertility-assessment-in-china 2025-08-06T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bracco-imaging-receives-nmpa-approval-for-sonovue-in-female-infertility-assessment-in-china 2025-08-06T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/esmo-2025-delivers-breakthrough-bladder-cancer-results-with-perioperative-immunotherapy-combinations 2025-08-06T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esmo-2025-delivers-breakthrough-bladder-cancer-results-with-perioperative-immunotherapy-combinations 2025-08-06T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/nxera-pharma-launches-comprehensive-obesity-pipeline-with-novel-oral-glp-1-agonist 2025-08-06T05:21:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nxera-pharma-launches-comprehensive-obesity-pipeline-with-novel-oral-glp-1-agonist 2025-08-06T05:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/bluerock-therapeutics-advances-bemdaneprocel-to-phase-iii-for-parkinson-s-disease-as-market-projected-to-reach-7-0-billion-by-2033 2025-08-06T03:00:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bluerock-therapeutics-advances-bemdaneprocel-to-phase-iii-for-parkinson-s-disease-as-market-projected-to-reach-7-0-billion-by-2033 2025-08-06T03:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/high-discontinuation-rates-plague-pediatric-clinical-trials-as-researchers-push-for-child-centric-design 2025-08-06T02:59:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-discontinuation-rates-plague-pediatric-clinical-trials-as-researchers-push-for-child-centric-design 2025-08-06T02:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-surges-57-following-fda-clearance-for-cid-103-kidney-transplant-rejection-therapy 2025-08-06T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-surges-57-following-fda-clearance-for-cid-103-kidney-transplant-rejection-therapy 2025-08-06T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/idmc-recommends-continuation-of-eli-002-7p-phase-2-trial-in-pancreatic-cancer-following-positive-interim-analysis 2025-08-06T01:28:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/idmc-recommends-continuation-of-eli-002-7p-phase-2-trial-in-pancreatic-cancer-following-positive-interim-analysis 2025-08-06T01:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/hmnc-brain-health-s-bh-200-shows-promising-results-in-phase-2-depression-trial-with-genetic-selection-tool 2025-08-06T01:28:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hmnc-brain-health-s-bh-200-shows-promising-results-in-phase-2-depression-trial-with-genetic-selection-tool 2025-08-06T01:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/nalu-medical-s-comfort-2-trial-establishes-first-level-1-evidence-for-permanent-peripheral-nerve-stimulation-in-chronic-pain 2025-08-06T01:28:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nalu-medical-s-comfort-2-trial-establishes-first-level-1-evidence-for-permanent-peripheral-nerve-stimulation-in-chronic-pain 2025-08-06T01:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/forcast-orthopedics-secures-series-a-funding-to-advance-novel-periprosthetic-joint-infection-therapies 2025-08-06T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/forcast-orthopedics-secures-series-a-funding-to-advance-novel-periprosthetic-joint-infection-therapies 2025-08-06T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-adopts-intact-nmr-spectroscopy-for-enhanced-quality-assessment-of-nanoemulsion-drug-formulations 2025-08-06T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-adopts-intact-nmr-spectroscopy-for-enhanced-quality-assessment-of-nanoemulsion-drug-formulations 2025-08-06T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/democratic-senators-challenge-fda-s-approval-of-juul-e-cigarettes-amid-conflict-of-interest-concerns 2025-08-06T01:26:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/democratic-senators-challenge-fda-s-approval-of-juul-e-cigarettes-amid-conflict-of-interest-concerns 2025-08-06T01:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-cgrp-antagonist-for-pediatric-migraine-prevention-as-ajovy-expands-to-children 2025-08-06T01:26:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-cgrp-antagonist-for-pediatric-migraine-prevention-as-ajovy-expands-to-children 2025-08-06T01:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/aurobindo-pharma-acquires-lannett-for-250m-to-expand-us-adhd-therapeutics-portfolio 2025-08-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aurobindo-pharma-acquires-lannett-for-250m-to-expand-us-adhd-therapeutics-portfolio 2025-08-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cho-plus-secures-10-4m-barda-contract-to-develop-cell-lines-for-filovirus-monoclonal-antibody-production 2025-08-05T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cho-plus-secures-10-4m-barda-contract-to-develop-cell-lines-for-filovirus-monoclonal-antibody-production 2025-08-05T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/promega-secures-patent-victory-against-aobious-in-luciferase-technology-dispute 2025-08-05T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promega-secures-patent-victory-against-aobious-in-luciferase-technology-dispute 2025-08-05T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/ategenos-secures-foundational-patent-for-smartpatch-platform-addressing-1t-medication-non-adherence-crisis 2025-08-05T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ategenos-secures-foundational-patent-for-smartpatch-platform-addressing-1t-medication-non-adherence-crisis 2025-08-05T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/flare-therapeutics-initiates-phase-1b-trial-of-first-in-class-pparg-inhibitor-fx-909-for-advanced-urothelial-cancer 2025-08-05T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/flare-therapeutics-initiates-phase-1b-trial-of-first-in-class-pparg-inhibitor-fx-909-for-advanced-urothelial-cancer 2025-08-05T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/kashiv-biosciences-partners-with-ms-pharma-for-mena-launch-of-omalizumab-biosimilar-adl-018 2025-08-05T21:25:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kashiv-biosciences-partners-with-ms-pharma-for-mena-launch-of-omalizumab-biosimilar-adl-018 2025-08-05T21:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/civicascript-announces-low-cost-ustekinumab-biosimilar-distribution-to-expand-access-to-inflammatory-disease-treatment 2025-08-05T21:25:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/civicascript-announces-low-cost-ustekinumab-biosimilar-distribution-to-expand-access-to-inflammatory-disease-treatment 2025-08-05T21:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-discontinues-praluent-supply-to-china-amid-global-demand-surge-and-local-competition 2025-08-05T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-discontinues-praluent-supply-to-china-amid-global-demand-surge-and-local-competition 2025-08-05T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/akyso-therapeutics-advances-long-acting-opioid-use-disorder-treatment-with-successful-phase-1a-trial-and-15m-nih-grant 2025-08-05T21:24:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akyso-therapeutics-advances-long-acting-opioid-use-disorder-treatment-with-successful-phase-1a-trial-and-15m-nih-grant 2025-08-05T21:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/vitiligo-treatment-pipeline-shows-promise-with-jak-inhibitors-and-novel-immunotherapies-in-phase-3-trials 2025-08-05T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vitiligo-treatment-pipeline-shows-promise-with-jak-inhibitors-and-novel-immunotherapies-in-phase-3-trials 2025-08-05T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/porosome-therapeutics-reports-breakthrough-alzheimer-s-platform-with-fda-validated-organoid-studies-and-ai-designed-therapeutics 2025-08-05T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/porosome-therapeutics-reports-breakthrough-alzheimer-s-platform-with-fda-validated-organoid-studies-and-ai-designed-therapeutics 2025-08-05T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/imperial-college-s-react-study-partners-with-dementia-trials-accelerator-to-transform-clinical-trial-recruitment 2025-08-05T21:23:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imperial-college-s-react-study-partners-with-dementia-trials-accelerator-to-transform-clinical-trial-recruitment 2025-08-05T21:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/biomark-diagnostics-doubles-laboratory-capacity-to-accelerate-lung-cancer-assay-commercialization 2025-08-05T17:54:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomark-diagnostics-doubles-laboratory-capacity-to-accelerate-lung-cancer-assay-commercialization 2025-08-05T17:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-ifinatamab-deruxtecan-receives-fda-breakthrough-designation-for-small-cell-lung-cancer 2025-08-05T17:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-ifinatamab-deruxtecan-receives-fda-breakthrough-designation-for-small-cell-lung-cancer 2025-08-05T17:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/epicrispr-biotechnologies-doses-first-patient-with-epi-321-novel-epigenetic-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-08-05T17:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/epicrispr-biotechnologies-doses-first-patient-with-epi-321-novel-epigenetic-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-08-05T17:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/ac-immune-reports-strong-immunogenicity-data-for-parkinson-s-disease-vaccine-in-phase-2-trial 2025-08-05T17:45:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ac-immune-reports-strong-immunogenicity-data-for-parkinson-s-disease-vaccine-in-phase-2-trial 2025-08-05T17:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/synox-therapeutics-completes-enrollment-in-phase-3-trial-of-emactuzumab-for-rare-joint-tumor 2025-08-05T17:45:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synox-therapeutics-completes-enrollment-in-phase-3-trial-of-emactuzumab-for-rare-joint-tumor 2025-08-05T17:45:30+00:00 hourly 0.9 https://trial.medpath.com/news/kyoto-university-develops-non-addictive-painkiller-adriana-as-morphine-alternative 2025-08-05T17:45:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyoto-university-develops-non-addictive-painkiller-adriana-as-morphine-alternative 2025-08-05T17:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-receives-fda-fast-track-designation-for-investigational-therapy 2025-08-05T17:44:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-pharmaceuticals-receives-fda-fast-track-designation-for-investigational-therapy 2025-08-05T17:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/novel-bacterial-consortium-aun-achieves-tumor-eradication-without-immune-system-dependence 2025-08-05T17:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-bacterial-consortium-aun-achieves-tumor-eradication-without-immune-system-dependence 2025-08-05T17:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/shattuck-labs-secures-103-million-to-advance-first-in-class-dr3-antibody-sl-325-through-phase-2-trials 2025-08-05T17:43:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shattuck-labs-secures-103-million-to-advance-first-in-class-dr3-antibody-sl-325-through-phase-2-trials 2025-08-05T17:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-for-412-million-expanding-rare-oncology-portfolio 2025-08-05T17:42:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-for-412-million-expanding-rare-oncology-portfolio 2025-08-05T17:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/ripk1-inhibitor-pipeline-shows-promise-despite-sanofi-setback-in-multiple-sclerosis 2025-08-05T17:42:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ripk1-inhibitor-pipeline-shows-promise-despite-sanofi-setback-in-multiple-sclerosis 2025-08-05T17:42:44+00:00 hourly 0.9 https://trial.medpath.com/news/fda-provides-positive-feedback-on-immutep-s-eftilagimod-alfa-for-head-and-neck-cancer-treatment 2025-08-05T17:42:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-provides-positive-feedback-on-immutep-s-eftilagimod-alfa-for-head-and-neck-cancer-treatment 2025-08-05T17:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/gensight-s-gene-therapy-shows-better-outcomes-when-administered-during-dynamic-phase-of-lhon-disease 2025-08-05T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensight-s-gene-therapy-shows-better-outcomes-when-administered-during-dynamic-phase-of-lhon-disease 2025-08-05T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/sophia-genetics-and-astrazeneca-expand-ai-partnership-to-optimize-breast-cancer-treatment-outcomes 2025-08-05T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sophia-genetics-and-astrazeneca-expand-ai-partnership-to-optimize-breast-cancer-treatment-outcomes 2025-08-05T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/yatiri-bio-acquires-ngenebioai-to-strengthen-ai-powered-proteomics-platform-for-precision-medicine 2025-08-05T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yatiri-bio-acquires-ngenebioai-to-strengthen-ai-powered-proteomics-platform-for-precision-medicine 2025-08-05T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/gut-metabolite-imidazole-propionate-identified-as-novel-atherosclerosis-driver-and-therapeutic-target 2025-08-05T17:38:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gut-metabolite-imidazole-propionate-identified-as-novel-atherosclerosis-driver-and-therapeutic-target 2025-08-05T17:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/israeli-researchers-achieve-first-long-term-growth-of-human-kidney-organoids-opening-path-to-regenerative-therapies 2025-08-05T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/israeli-researchers-achieve-first-long-term-growth-of-human-kidney-organoids-opening-path-to-regenerative-therapies 2025-08-05T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/contract-manufacturing-industry-report-reveals-impact-of-global-conflicts-and-inflation-on-pharmaceutical-production 2025-08-05T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/contract-manufacturing-industry-report-reveals-impact-of-global-conflicts-and-inflation-on-pharmaceutical-production 2025-08-05T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-generic-drug-approval-delays-threaten-patient-access-and-healthcare-cost-savings 2025-08-05T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-generic-drug-approval-delays-threaten-patient-access-and-healthcare-cost-savings 2025-08-05T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/nih-launches-escape-trial-to-test-maternal-diet-s-role-in-preventing-early-food-allergies-in-infants 2025-08-05T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-launches-escape-trial-to-test-maternal-diet-s-role-in-preventing-early-food-allergies-in-infants 2025-08-05T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/news/gedeon-richter-reintroduces-dydrogesterone-only-hrt-option-to-uk-market-after-17-year-absence 2025-08-05T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gedeon-richter-reintroduces-dydrogesterone-only-hrt-option-to-uk-market-after-17-year-absence 2025-08-05T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/mdxhealth-acquires-bio-techne-s-exodx-prostate-test-platform-in-15-million-strategic-deal 2025-08-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mdxhealth-acquires-bio-techne-s-exodx-prostate-test-platform-in-15-million-strategic-deal 2025-08-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-reveals-chronic-spontaneous-urticaria-patients-face-greater-disease-burden-than-other-inflammatory-skin-conditions 2025-08-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-reveals-chronic-spontaneous-urticaria-patients-face-greater-disease-burden-than-other-inflammatory-skin-conditions 2025-08-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/180-life-sciences-pivots-from-biotech-to-ethereum-treasury-strategy-with-581-million-in-funding 2025-08-05T13:36:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/180-life-sciences-pivots-from-biotech-to-ethereum-treasury-strategy-with-581-million-in-funding 2025-08-05T13:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-sets-ambitious-900m-935m-voxzogo-revenue-target-for-2025-amid-strategic-portfolio-restructuring 2025-08-05T13:35:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-sets-ambitious-900m-935m-voxzogo-revenue-target-for-2025-amid-strategic-portfolio-restructuring 2025-08-05T13:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/axogen-raises-2025-revenue-growth-target-to-17-as-avance-nerve-graft-bla-approval-approaches 2025-08-05T13:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axogen-raises-2025-revenue-growth-target-to-17-as-avance-nerve-graft-bla-approval-approaches 2025-08-05T13:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/sensei-biotherapeutics-advances-vista-targeting-cancer-therapy-with-q2-2025-results-and-esmo-presentation 2025-08-05T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensei-biotherapeutics-advances-vista-targeting-cancer-therapy-with-q2-2025-results-and-esmo-presentation 2025-08-05T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/polpharma-biologics-and-fresenius-kabi-partner-on-vedolizumab-biosimilar-for-inflammatory-bowel-disease 2025-08-05T13:31:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polpharma-biologics-and-fresenius-kabi-partner-on-vedolizumab-biosimilar-for-inflammatory-bowel-disease 2025-08-05T13:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/mcl-1-inhibitors-advance-toward-clinical-breakthrough-with-over-12-drugs-in-development-pipeline 2025-08-05T13:29:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mcl-1-inhibitors-advance-toward-clinical-breakthrough-with-over-12-drugs-in-development-pipeline 2025-08-05T13:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/ethris-initiates-phase-2a-trial-of-novel-mrna-therapy-eth47-for-viral-triggered-asthma-exacerbations 2025-08-05T13:29:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethris-initiates-phase-2a-trial-of-novel-mrna-therapy-eth47-for-viral-triggered-asthma-exacerbations 2025-08-05T13:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/nucleus-network-acquires-hammersmith-medicines-research-to-create-global-early-phase-clinical-trial-network 2025-08-05T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nucleus-network-acquires-hammersmith-medicines-research-to-create-global-early-phase-clinical-trial-network 2025-08-05T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/fapon-biopharma-enrolls-first-patient-in-phase-i-trial-of-fp008-novel-anti-pd-1-fusion-protein-for-solid-tumors 2025-08-05T13:28:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fapon-biopharma-enrolls-first-patient-in-phase-i-trial-of-fp008-novel-anti-pd-1-fusion-protein-for-solid-tumors 2025-08-05T13:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-stem-cell-therapy-shows-promise-for-newborn-brain-injury-in-passion-safety-trial 2025-08-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-stem-cell-therapy-shows-promise-for-newborn-brain-injury-in-passion-safety-trial 2025-08-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/korean-biotech-hyundai-bioscience-reports-positive-phase-ii-results-for-oral-covid-19-treatment-cp-cov03 2025-08-05T10:58:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-biotech-hyundai-bioscience-reports-positive-phase-ii-results-for-oral-covid-19-treatment-cp-cov03 2025-08-05T10:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-plans-generic-semaglutide-launch-in-canada-with-up-to-70-price-reduction 2025-08-05T09:32:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-plans-generic-semaglutide-launch-in-canada-with-up-to-70-price-reduction 2025-08-05T09:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/taconic-and-cyagen-form-strategic-partnership-to-expand-access-to-16000-genetically-engineered-mouse-models 2025-08-05T09:30:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taconic-and-cyagen-form-strategic-partnership-to-expand-access-to-16000-genetically-engineered-mouse-models 2025-08-05T09:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/tempest-therapeutics-advances-phase-3-trial-of-tpst-1120-combination-for-hepatocellular-carcinoma 2025-08-05T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempest-therapeutics-advances-phase-3-trial-of-tpst-1120-combination-for-hepatocellular-carcinoma 2025-08-05T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-dyanavel-xr-extended-release-amphetamine-for-adhd-treatment-in-adults-and-children 2025-08-05T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-dyanavel-xr-extended-release-amphetamine-for-adhd-treatment-in-adults-and-children 2025-08-05T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/metis-technologies-raises-rmb-400-million-series-d-to-advance-ai-driven-nanodelivery-platform 2025-08-05T05:30:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metis-technologies-raises-rmb-400-million-series-d-to-advance-ai-driven-nanodelivery-platform 2025-08-05T05:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/cyclacel-s-plogosertib-shows-promise-against-biliary-tract-cancer-in-preclinical-study 2025-08-05T05:29:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cyclacel-s-plogosertib-shows-promise-against-biliary-tract-cancer-in-preclinical-study 2025-08-05T05:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-and-efficacy-of-trastuzumab-biosimilar-ct-p6-in-her2-positive-gastric-cancer 2025-08-05T05:29:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-safety-and-efficacy-of-trastuzumab-biosimilar-ct-p6-in-her2-positive-gastric-cancer 2025-08-05T05:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/sarilumab-demonstrates-significant-quality-of-life-improvements-in-polymyalgia-rheumatica-phase-3-trial 2025-08-05T05:04:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarilumab-demonstrates-significant-quality-of-life-improvements-in-polymyalgia-rheumatica-phase-3-trial 2025-08-05T05:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/syndax-reports-strong-q2-2025-results-with-revuforj-revenue-growth-and-pending-fda-approval-for-npm1-aml 2025-08-05T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/syndax-reports-strong-q2-2025-results-with-revuforj-revenue-growth-and-pending-fda-approval-for-npm1-aml 2025-08-05T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-study-reveals-hidden-cancer-cells-in-42-of-ovarian-cancer-patients-in-clinical-remission 2025-08-05T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-study-reveals-hidden-cancer-cells-in-42-of-ovarian-cancer-patients-in-clinical-remission 2025-08-05T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/grifols-alzheimer-vaccine-abvac40-demonstrates-53-reduction-in-cognitive-decline-risk-in-phase-2-trial 2025-08-05T01:27:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grifols-alzheimer-vaccine-abvac40-demonstrates-53-reduction-in-cognitive-decline-risk-in-phase-2-trial 2025-08-05T01:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-pharmaceuticals-discontinues-vx-993-development-after-phase-2-failure-in-acute-pain 2025-08-05T01:27:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-pharmaceuticals-discontinues-vx-993-development-after-phase-2-failure-in-acute-pain 2025-08-05T01:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/first-commercial-brain-gene-therapy-treatments-delivered-in-us-using-clearpoint-neuro-s-smartflow-cannula 2025-08-05T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-commercial-brain-gene-therapy-treatments-delivered-in-us-using-clearpoint-neuro-s-smartflow-cannula 2025-08-05T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-study-confirms-safety-and-efficacy-of-aflibercept-biosimilar-pavblu-in-6313-patients 2025-08-05T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-study-confirms-safety-and-efficacy-of-aflibercept-biosimilar-pavblu-in-6313-patients 2025-08-05T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/redwire-launches-spacemd-to-commercialize-space-grown-pharmaceutical-crystals 2025-08-05T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redwire-launches-spacemd-to-commercialize-space-grown-pharmaceutical-crystals 2025-08-05T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/sonelokimab-shows-promising-24-week-results-in-phase-2-psoriatic-arthritis-trial 2025-08-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonelokimab-shows-promising-24-week-results-in-phase-2-psoriatic-arthritis-trial 2025-08-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-in-human-hiv-vaccine-trial-begins-in-africa-using-novel-gorilla-adenovirus-vector-platform 2025-08-04T21:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-in-human-hiv-vaccine-trial-begins-in-africa-using-novel-gorilla-adenovirus-vector-platform 2025-08-04T21:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-reports-91-revenue-surge-driven-by-briumvi-multiple-sclerosis-treatment 2025-08-04T21:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-reports-91-revenue-surge-driven-by-briumvi-multiple-sclerosis-treatment 2025-08-04T21:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-addresses-safety-concerns-as-pyrukynd-receives-saudi-approval-for-thalassemia 2025-08-04T21:31:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-pharmaceuticals-addresses-safety-concerns-as-pyrukynd-receives-saudi-approval-for-thalassemia 2025-08-04T21:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/tearcare-system-demonstrates-cost-savings-and-superior-outcomes-compared-to-cyclosporine-in-dry-eye-treatment 2025-08-04T21:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tearcare-system-demonstrates-cost-savings-and-superior-outcomes-compared-to-cyclosporine-in-dry-eye-treatment 2025-08-04T21:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/rapid-dose-therapeutics-submits-quickstrip-nicotine-oral-film-for-health-canada-approval 2025-08-04T21:30:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapid-dose-therapeutics-submits-quickstrip-nicotine-oral-film-for-health-canada-approval 2025-08-04T21:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/car-macrophages-generated-in-situ-via-mrna-loaded-extracellular-vesicles-show-promise-against-lung-metastasis 2025-08-04T21:30:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-macrophages-generated-in-situ-via-mrna-loaded-extracellular-vesicles-show-promise-against-lung-metastasis 2025-08-04T21:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/combination-therapy-achieves-15-month-progression-free-survival-in-advanced-large-cell-neuroendocrine-lung-carcinoma 2025-08-04T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/combination-therapy-achieves-15-month-progression-free-survival-in-advanced-large-cell-neuroendocrine-lung-carcinoma 2025-08-04T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/xoma-acquires-struggling-biotechs-hillevax-and-lava-therapeutics-in-strategic-consolidation-move 2025-08-04T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xoma-acquires-struggling-biotechs-hillevax-and-lava-therapeutics-in-strategic-consolidation-move 2025-08-04T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/agios-pharmaceuticals-faces-fda-delay-for-pyrukynd-thalassemia-approval-amid-safety-concerns 2025-08-04T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-pharmaceuticals-faces-fda-delay-for-pyrukynd-thalassemia-approval-amid-safety-concerns 2025-08-04T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/bmi-organbank-receives-fda-breakthrough-device-designation-for-room-temperature-kidney-preservation-technology 2025-08-04T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bmi-organbank-receives-fda-breakthrough-device-designation-for-room-temperature-kidney-preservation-technology 2025-08-04T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-receives-fda-clearance-for-first-tags-powered-respiratory-test-detecting-four-major-viruses 2025-08-04T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-receives-fda-clearance-for-first-tags-powered-respiratory-test-detecting-four-major-viruses 2025-08-04T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-bath-develops-oral-delivery-system-for-injectable-protein-drugs 2025-08-04T21:26:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-bath-develops-oral-delivery-system-for-injectable-protein-drugs 2025-08-04T21:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-medicines-reports-56-seizure-reduction-with-vormatrigine-despite-stock-decline 2025-08-04T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-medicines-reports-56-seizure-reduction-with-vormatrigine-despite-stock-decline 2025-08-04T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/tg-therapeutics-initiates-phase-3-trial-for-subcutaneous-briumvi-in-multiple-sclerosis 2025-08-04T17:42:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tg-therapeutics-initiates-phase-3-trial-for-subcutaneous-briumvi-in-multiple-sclerosis 2025-08-04T17:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/tharimmune-advances-th104-as-national-security-solution-against-weaponized-fentanyl-secures-5-47m-funding 2025-08-04T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tharimmune-advances-th104-as-national-security-solution-against-weaponized-fentanyl-secures-5-47m-funding 2025-08-04T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-expands-real-world-data-network-by-25-adding-5-billion-administrative-records 2025-08-04T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onemednet-expands-real-world-data-network-by-25-adding-5-billion-administrative-records 2025-08-04T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/sonnet-biotherapeutics-expands-son-1010-trial-after-promising-response-rate-in-platinum-resistant-ovarian-cancer 2025-08-04T17:35:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonnet-biotherapeutics-expands-son-1010-trial-after-promising-response-rate-in-platinum-resistant-ovarian-cancer 2025-08-04T17:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/pulsecare-medical-s-nxpfatm-receives-nmpa-approval-as-world-s-first-nanosecond-pulsed-field-ablation-system 2025-08-04T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pulsecare-medical-s-nxpfatm-receives-nmpa-approval-as-world-s-first-nanosecond-pulsed-field-ablation-system 2025-08-04T17:35:21+00:00 hourly 0.9